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RESUMO 
 
O objetivo do presente estudo foi avaliar a cinética do desenvolvimento de 
biofilmes de Candida albicans em superfícies de corpos de prova, sob a influência de películas 
adsorvidas, e os efeitos anti-biofilme dos antifúngicos Anfotericina B (AB), Fluconazol (FLU) 
e Nistatina (NYS) e dos extratos hidroalcoólico (FEHi) e seco (DEHi) da casca 
de Handroanthus impetiginosus através de modelos de ensaios in vitro. As amostras foram 
submersas em sistemas de pré-condicionamento: PBS, saliva artificial (AS), soro fetal bovino 
(FBS) e AS + FBS (1: 1). As células planctônicas recém-cultivadas foram incubadas em placas 
de microdiluição, contendo as amostras e o meio apropriado, por 1½h (fase de adesão: PBS), 
8h (fase inicial: YNB), 24h (fase intermediária: YNB) e 48h (fase de maturação: YNB). A 
concentração inibitória mínima do biofilme séssil (SMIC) foi realizada pelo método de 
microdiluição em caldo e a bioatividade nos biofilmes foi monitorada pelo ensaio XTT. A 
viabilidade celular, a biomassa relativa do biofilme (m3) e a espessura do biofilme (µm) foram 
avaliadas por microscopia de varredura a laser confocal (CLSM). A morfologia ultraestrutural 
foi analisada por Microscópio Eletrônico de Varredura (MEV). Maiores bioatividades foram 
registradas na presença de SFB. Em média, os biofilmes tratados com FLU e AB foram 
parcialmente inibidos dependentemente da dose, enquanto que NYS inibiu completamente a 
partir de concentrações de 15,6 ou 62,5 µg/ml, conforme adoção de critérios. Os tratamentos 
com agentes antifúngicos (concentrações idênticas) não mostraram diferenças estatísticas aos 
parâmetros biológicos (células não viáveis) e de parâmetros de magnitude (biomassa e 
espessura relativa). Em média, FEHi mostrou inibição das atividades metabólicas 100 mg/ml 
(maior ação em 1½h e 8h). SMIC80 de FEHi foi crescentemente elevada ao longo do 
desenvolvimento do biofilme. Em média, DEHi mostrou inibição parcial das atividades 
metabólicas (maior ação em 8h e 24h). SMIC80 de DEHi não foi observada nas concentrações 
testadas. FEHi e DEHi atuaram igualmente sobre os parâmetros biológico (percentual de células 
não viáveis) e de grandeza (biomassa relativa e espessura) dos biofilmes de C. albicans. A 
espessura dos biofilmes foi maior na fase de maturação, enquanto que os percentuais de células 
não viáveis e biomassa relativa do biofilme foram invariáveis ao longo do desenvolvimento do 
biofilme. As ações de FEHi e DEHi produziram efeitos variáveis quanto ao dimorfismo, volume 
microbiano e densidade populacional microbiana, especialmente nas fases de adesão e inicial 
de desenvolvimento do biofilme de C. albicans. As características morfológicas ultra 
estruturais são dependentes do extrato de H. impetiginosus e das fases de desenvolvimento dos 
biofilmes de C. albicans, sugerindo diferenças na composição fitoquímica de ambos os 
extratos. Os dados sugerem que há redução parcial (FLU e AB) ou efetiva (NYS) da atividade 
metabólica da cinética de crescimento dos biofilmes de C. albicans, dependendo do tempo e do 
antifúngico e suas concentrações. FEHi e DEHi apresentam efetividades dose-, superfície- e 
tempo-dependentes. Contudo, FEHi tem maior ação anti-biofilme, sugerindo sua potencial 
aplicação ao desenvolvimento de novos fármacos e produtos relacionados. 
 
 
 
 
 
 
 
 
Palavras chaves: Candida albicans; Antifúngicos; Biofilme; Resina Dentária; Handroanthus 
impetiginosus. 
 
 
 
ABSTRACT 
 
The aim of the present study was to evaluate the kinetics of Candida albicans 
biofilm development on specimen surfaces under the influence of adsorbed films, and the anti-
biofilm effects of antifungals: Amphotericin B (AB), Fluconazole (FLU) and Nystatin (NYS) 
and hydroalcoholic (FEHi) and dry (DEHi) extracts of Handroanthus impetiginosus bark by in 
vitro test models. The samples were submerged in preconditioning systems: PBS, artificial 
saliva (AS), fetal bovine serum (FBS) and AS + FBS (1: 1). The newly cultivated planktonic 
cells were incubated in microdilution plates containing the samples and the appropriate medium 
for 1½h (adhesion phase: PBS), 8h (initial phase: YNB), 24h (intermediate phase: YNB) and 
48h (phase maturation: YNB). The minimum inhibitory concentration of the sessile biofilm 
(SMIC) was performed by the broth microdilution method and the bioactivity in the biofilms 
was monitored by the XTT assay. Cell viability, relative biofilm biomass (m3) and biofilm 
thickness (µm) were evaluated by confocal laser scanning microscopy (CLSM). The 
ultrastructural morphology was analyzed by Scanning Electron Microscope (SEM). Higher 
bioactivities were recorded in the presence of FBS. On average, FLU and AB-treated biofilms 
were partially dose-dependent inhibited, whereas NYS inhibited completely from 
concentrations of 15.6 or 62.5 µg/ml, as criteria were adopted. Treatments with antifungal 
agents (identical concentrations) showed no statistical differences between biological 
parameters (non-viable cells) and magnitude parameters (biomass and relative thickness). On 
average, FEHi showed inhibition of metabolic activities 100 mg / ml (highest action at 1½h 
and 8h). FEHi's SMIC80 was increasingly elevated throughout biofilm development. On 
average, DEHi showed partial inhibition of metabolic activities (highest action at 8h and 24h). 
DEHi SMIC80 was not observed at the concentrations tested. FEHi and DEHi also affected the 
biological (percentage of non-viable cells) and magnitude (relative biomass and thickness) 
parameters of C. albicans biofilms. The thickness of the biofilms was higher in the maturation 
phase, while the percentages of non-viable cells and relative biomass of the biofilm were 
invariable throughout the biofilm development. The actions of FEHi and DEHi produced 
variable effects on dimorphism, microbial volume and microbial population density, especially 
in the adhesion and early stages of development of C. albicans biofilm. The ultrastructural 
morphological characteristics are dependent on H. impetiginosus extract and on the 
developmental stages of C. albicans biofilms, suggesting differences in the phytochemical 
composition of both extracts. The data suggest that there is a partial (FLU and AB) or effective 
(NYS) reduction in the metabolic activity of C. albicans biofilm growth kinetics, depending on 
time and antifungal and their concentrations. FEHi and DEHi have dose-, surface- and time-
dependent effectiveness. However, FEHi has greater anti-biofilm action, suggesting its 
potential application to the development of new drugs and related products. 
 
 
Keywords: Candida albicans; Antifungals; Biofilm; dental resin; Handroanthus 
impetiginosus. 
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1 INTRODUÇÃO 
 
A estomatite afeta grande parte dos indivíduos usuários de próteses totais ou parciais 
(35% à 75%), dependendo da população estudada e compreende uma reação inflamatória da 
mucosa oral sob o material da prótese (1). Sua classificação baseia-se em critérios clínicos e 
são divididos em três tipos: Tipo I: inflamação localizada, punctiforme ou pontos de hiperemia, 
que se manifesta por discretas áreas de inflamação focal do palato, localizado e limitado aos 
ductos das glândulas salivares palatinas menores; Tipo II: eritema difuso: observa-se eritema 
generalizado abrangendo parte ou toda a área coberta pela prótese; Tipo III: hiperplasia papilar 
do palato: caracteriza-se pela presença de nódulos ou placas (geralmente localizados na parte 
central do palato) e eritema da mucosa de suporte da prótese (2,3). A estomatite protética é 
considerada uma infecção multifatorial associada a falta de higienização, má adaptação ou 
desgaste da prótese, além de diversos fatores predisponentes como o tabagismo, diabetes, 
doenças sistêmicas, declínio da imunidade (1,4–7). Entretanto, espécies de Candida têm sido 
amplamente descritas na literatura como principais patógenos causadores da estomatite em 
usuários de prótese, sendo a Candida albicans a levedura mais prevalente (≥70%) (1,8–10). 
O uso de próteses dentárias pode causar uma alteração no microambiente bucal como 
diminuição do fluxo salivar, pH, oxigênio, presença de exsudato inflamatório e disponibilidade 
de nutrientes, condições que favorecem a formação de biofilme (1), o qual se desenvolve sobre 
a superfície protética e pode ocasionar consequentemente a estomatite por prótese (11,12). 
O tratamento da estomatite deve ser com base em sua etiologia multifatorial, no qual 
consiste principalmente na substituição da prótese antiga por uma com melhor ajuste e adaptada 
anatomicamente, afim de evitar a oclusão traumática, terapia antifúngica e medidas profiláticas 
de higiene bucal (13,14). Para reduzir os efeitos traumáticos que a prótese pode exercer sobre 
a mucosa oral (normal ou atrófica) durante a mastigação, o uso de materiais macios e resilientes 
tem sido empregado com propósito terapêutico, permitindo uma melhor recuperação do tecido 
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exposto a prótese (13), entretanto, a rugosidade superficial desses materiais o tornam 
susceptíveis a colonização por Candida (15–17). 
A formação de biofilme nas superfícies da prótese e da mucosa associada a presença de 
fatores intrínsecos da cavidade oral (e.g. pH, disponibilidade de nutrientes, composição gasosa, 
além da película salivar e possível exsudato inflamatório) podem exercer influência sobre o 
desenvolvimento desses biofilmes e na susceptibilidade aos agentes antifúngicos utilizados na 
terapêutica atual, como os antifúngicos azóis (e.g., como o fluconazol tem sido amplamente 
utilizado para o tratamento antifúngico sistêmico), e os antifúngicos polienos (e.g., como a 
anfotericina B e a nistatina usados como solução tópica ou aplicados na superfície da prótese 
antes de sua utilização). A resistência dos biofilmes sobre a terapêutica convencional aos 
antifúngicos geram limitações ao tratamento e possibilitam a recorrência da infecção (1,18–20). 
Devido ao aumento da resistência à antifúngicos, alternativas de prevenção, tratamentos 
e a busca por novos biocomponentes com potencial antifúngico provenientes de plantas 
medicinais (e.g. extratos, metabólitos secundários, óleos essenciais) são importantes e têm sido 
amplamente descritos na literatura (21–23). 
Dentre as plantas medicinais, o Handroanthus impetiginosus (Mart. ex DC.) Mattos 
(popularmente conhecida como Ipê-roxo ou Pau D’arco), é uma árvore que pertence à família 
das plantas Bignoniaceae, podendo ser encontrada nas florestas tropicais da América do Sul, 
particularmente no Brasil. Tem sido descrita na literatura como potencial fitoterápico, sendo 
utilizado farmacologicamente como tratamento de diversas condições clinicas (e.g. agentes 
antiangiogênicos, antimicrobianos, antinociceptivos e antiedematogênicos, antioxidantes, 
agentes cicatrizantes e agentes antineoplásicos). O produto extraído da casca dessa árvore 
possui em sua composição fitoquímica a presença de componentes como naftoquinonas, 
furanonaftoquinonas, antraquinonas, derivados do ácido benzóico, derivados de benzaldeído, 
iridóides, cumarinas, flavonóides e glicosídeos fenilpropanóides, sendo o lapachol e β 
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lapachona descritos por desempenharem efeito relevante contra cepas de Candida albicans e 
espécies relacionadas (24–26). No entanto, não há relatos na literatura explorando a atividade 
de extratos de H. impetiginosus frente a sua capacidade anti-biofilme. 
Considerando a incidência da estomatite protética por Candida albicans, sua capacidade 
de formação de biofilmes, o aumento da resistência aos antifúngicos e sua influência no 
tratamento de infecções, a avaliação dos tratamentos convencionais (e.g. fluconazol, 
anfotericina B e nistatina) e de tratamento alternativo (H. impetiginosus) sobre a cinética do 
desenvolvimento de biofilmes devem ser realizados afim de complementar o conhecimento 
científico, além de promover um tratamento efetivo e consequentemente bem estar dos 
pacientes.  
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ABSTRACT 
Objective: The aim was to investigate the growth kinetics of C. albicans biofilms, absorved 
surfaces of specimens and under the influence of adsorb films, and to evaluate the antibiofilm 
efficacy of antifungal agents: Amphotericin B (AB), Fluconazole (FLU), and Nystatin (NYS). 
Methods: Specimens (Silagum-Comfort Soft Relining) were submerged in preconditioning 
systems: PBS, artificial saliva (AS), fetal bovine serum (FBS), and AS+FBS. Planktonic cells 
were incubated (PBS + specimens) for 1½ hour (adhesion phase) and washed with PBS 
solution. Then, specimens were incubated (YNB + glucose) for 8h (initial phase), 24h 
(intermediate phase), and 48h (maturation phase). The biofilm sessile minimum inhibitory 
concentration (SMIC) was performed by the broth microdilution method (7.8125–500 µg/ml). 
Bioactivity of biofilms was monitored by XTT assay and the cell viability, relative biomass 
(mm3), and thickness of the biofilm (µm) were evaluated by CLSM. 
Results: Highest bioactivities were registered in the presence of FBS. Biofilms treated with 
FLU and AB were partially inhibited in a dose-dependent manner. NYS inhibited mainly from 
15.6 or 62.5 µg/ml. The treatments with antifungal agents (identical concentrations) showed 
no statistical differences, neither for biological parameter (non-viable cells) nor for magnitude 
parameters (relative biomass and thickness). 
Conclusion: Data suggest that there is partial (FLU and AB) or more effective (NYS) reduction 
of the metabolic activity of the growth kinetics of C. albicans biofilms, depending on the time 
and on the antifungal and its concentrations. FLU, AB, and NYS at the same concentrations 
also exert effects on the biological parameters and of magnitude. 
 
Keywords: Candida albicans, Antifungals, Biofilm, dental resin 
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INTRODUCTION 
Stomatitis affects many individuals who are users of total or partial prostheses (35% to 
75%) depending on the studied population, and comprises an inflammatory reaction of the 
oral mucosa under the prosthesis material.1 This is considered a multifactorial infection 
associated with lack of hygiene, poor adaptation to or wear of the prosthesis, besides several 
predisposing factors such as smoking habit, diabetes, systemic diseases, and decline of 
immunity.1,2,3,4,5 However, Candida species has been widely described in the literature as the 
main pathogen causing stomatitis in prosthesis users, being Candida albicans the most 
prevalent yeast (≥70%).1,6,7,8 
The use of dental prostheses may cause changes in the oral microenvironment, such as 
decreased salivary flow, pH, oxygen, presence of inflammatory exudate, and nutrient 
availability, conditions that favor the formation of biofilm,1 which is developed on the 
prosthetic surface and consequently causes prosthetic stomatitis.9,10 
The treatment of stomatitis should be based on its multifactorial etiology, which mainly 
consists in replacing the old prosthesis with one with better fit and anatomically adapted, in 
order to avoid traumatic occlusion, antifungal therapy, and prophylactic measures of oral 
hygiene.11,12 
To reduce the traumatic effects that the prosthesis can exert on the oral mucosa (normal or 
atrophic) during chewing, the use of soft and resilient materials has been employed with 
therapeutic purpose, allowing a better recovery of the tissue exposed to the prosthesis.11 
However, the surface roughness of these materials makes them susceptible to Candida 
colonization, 13,14,15 and local factors of the oral environment, such as salivary presence and 
inflammatory exudate, can influence in the formation of biofilms.1,16,17 
Formation of biofilm on the surfaces of the prosthesis and mucosa associated with presence of 
intrinsic factors of the oral environment influence in the susceptibility to antifungal agents 
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and, in the current therapy, to azole-based antifungals (e.g., as fluconazole has been widely 
used for systemic antifungal treatment), and polyene-based antifungals (e.g., as amphotericin 
B and nystatin used as topical solution or applied to the surface of the prosthesis prior to its 
use). However, recurrence of infection is frequent after treatment.18 
Considering the data on the incidence of stomatitis by Candida species in prosthesis users and 
their clinical repercussion, we evaluated the growth kinetics of C. albicans biofilms on the 
surfaces of specimens produced based on a prosthetic rebase (vinyl polysiloxane) and under 
the influence of adsorb films, and the antibiofilm efficacy of antifungal agents commonly 
used in the treatment of this disease. 
 
MATERIAL AND METHODS 
Specimens 
Specimens, with surfaces freely exposed to the growth conditions of the biofilm and 
measuring 1.5 cm2 (0.8 cm of  and 0.2 cm high;  hrr2A   ), were obtained from 
flexible material (vinyl polysiloxane) for rebase of dental prosthesis (Silagum-Comfort Soft 
Relining, ref. # 909951, batches 735776 and 761633, DMG Chemisch-Pharmazeutische, 
Hamburg, Germany) using stainless steel molds, which were varnished (Silagum-Comfort 
Verniz, ref. # 909089, batch 748329, DMG Chemisch-Pharmazeutische, Hamburg, Germany) 
according to the manufacturer’s instructions, and sterilized by hydrogen peroxide plasma. 
 
Culture of planktonic yeasts  
Yeasts of the species C. albicans ATCC 90028, newly developed on the SDA medium 
(Sabouraud Dextrose Agar, Cat. # CM0041B, Thermo Fisher Scientific, SP, Brazil), were 
cultivated [Laboratory Bottles, Cód. # BOE 5080365, Boeckel + Co (GmbH + Co), Hamburg, 
Germany] in 100 mL of YEPD medium YEPD (yeast extract 1% wt/vol, peptone 2% wt/vol, 
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dextrose 2% wt/vol) at 37 C for 24 hours at 150 rpm (orbital shaking incubator TE-4200, 
Tecnal Equipamentos para Laboratório Ltda., Piracicaba, SP, Brazil). These cultures were 
transferred to Falcon tubes (50mL, Corning Inc., Corning, NY, USA) and centrifuged at 2500 
 g (Centrifuge, model 5417R, Eppendorf do Brasil Ltda., São Paulo, Brazil) for 5 minutes at 
4  C and washed three times in 20 mL sterile PBS solution (100 mM NaCl, 100 mM 
NaH2PO4, pH 7.2), each wash being subjected to the same centrifugal force. For the biofilm 
assays, yeast cells were adjusted to a concentration of 1  107 UFC.mL-1 of PBS solution 
using spectrophotometer (Thermo Scientific Multiskan GO UV/Vis, Microplate and Cuvette 
Spectrophotometer, ref. # 51119200, Thermo Fisher Scientific Inc., Waltham, MA, USA) 
with wavelength of 600 nm (T = 10%  A 600 nm = 2 – log10 %T  A 600 nm = 1,0).19,20,21 
 
Preconditioning systems  
A total of four preconditioning systems potentially capable of generating adsorb films 
on specimens were studied: wash solution for planktonic yeast cells (PBS), artificial saliva 
(AS), fetal bovine serum (FBS), and artificial saliva and fetal bovine serum in the 1:1 ratio 
(AS+FBS).  
Artificial saliva (mucin, 35 g/L; xylitol, 20 g/L; potassium chloride, 1.2 g/L; sodium chloride, 
0.85 g/L; magnesium chloride hexahydrate, 0.05 g/L; calcium chloride hexahydrate, 0.2 g/L 
and dipotassium phosphate, 0.35 g/L)22 was sterilized by filtration KASVI – model K15-1150) 
and stored at 20 C up to the time of use. Fetal bovine serum was commercially acquired 
(Fetal Bovine Serum, qualified, E.U.-approved, South America origin, Gibco, Cat. # 
10270106, Thermo Fisher Scientific, SP, Brazil), inactivated at 56  C for 30 minutes and 
stored at -20  C until further use.  
Prior to biofilm assays, groups of specimens were kept submerged [Laboratory Bottles, Cód. 
# BOE 5080365, Boeckel + Co (GmbH + Co), Hamburg, Germany] in their respective 
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preconditioning systems at 37 C overnight under slight agitation (orbital shaking incubator 
TE-4200, Tecnal Equipamentos para Laboratório Ltda., Piracicaba, SP, Brazil).23 Shortly 
after, these specimens were aseptically transferred to microdilution plate wells (48-well cell 
culture microplates, flat-bottom, Corning Inc., Corning, NY, USA). 
 
Development of control biofilms 
For developing of control biofilms, 500-L aliquots of C. albicans yeast cells (1107 
UFC.mL-1 of PBS solution) were transferred to microdilution plates (48-well cell culture 
microplates, flat-bottom, Corning Inc., Corning, NY, USA) containing the specimens, and 
statically incubated at 37 C for 1½ hour (adhesion phase). Shortly after, wells containing the 
specimens were aspirated and thoroughly washed with sterile PBS solution (2 500 L) to 
remove non-adherent yeast cells (planktonic). Then, specimens were transferred to new 
microdilution plates containing 500 L of YNB broth (Yeast Nitrogen Base, Invitrogen, Cat. 
# Q30007, Thermo Fisher Scientific, SP, Brazil) supplemented with glucose (100 mM), and 
incubated at 37 C under 75-rpm agitation (Thermo Shaker Dry Block, mod: NI1364 – Nova 
Intruments, SP, Brazil), during three growth times of the biofilm: 8 hours (initial phase), 24 
hours (intermediate phase), and 48 hours (maturation phase).24,25 Microdilution plates 
containing YNB broth and specimens belonging to distinct preconditioning groups and 
growth times of biofilms, but without aliquots of yeast cells, were used as sterility controls 1. 
All assays were systematically performed in triplicate. 
 
Antibiofilm sensitivity test 
The determination of the biofilm sessile minimum inhibitory concentration (SMIC), 
against the growth kinetics of C. albicans biofilms in specimens, was performed by the broth 
microdilution method, partially based on the fundamentals established by the Clinical and 
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Laboratory Standards Institute,26 employing antifungal agents amphotericin B (polyene; CAS 
# 1397-89-3; Power g/mg; Sigma Chemical Co. and Cat. # A2411), fluconazole (triazole; 
CAS # 86386-73-4; Sigma Chemical Co. and Cat. # F8929), and nystatin (polyene macrolide; 
CAS # 1400-61-9; Power 4,400 IU/mg  1 IU corresponds to 0.0002059 mg; Calbiochem 
and Cat. # 475921). 
Standard solutions of antifungal agents were prepared, sterilized by filtration (Millipore 
Corporation, hydrophilic PVDF Durapore membrane filter, 0.22 m,  47 mm, Cat. # GVWP 
047 00) and stocked in glass vials of 250 mL [Laboratory Bottles, Cód. # BOE 5080365, 
Boeckel + Co (GmbH + Co), Hamburg, Germany] at 70 C up to the time of use. Tests were 
conducted on microdilution plates (48-well cell culture microplates, flat-bottom, Corning Inc., 
Corning, NY, USA) containing 500 µL of YNB per added well of the antifungal test at the 
final preestablished concentrations (500 µg.mL-1 up to 7.8125 µg.mL-1). 
C. albicans biofilms against previously preconditioned test specimens (PBS, AS, FBS, and 
AS+FBS) and in different development phases (1½, 8, 24, and 48 hours), were carefully 
washed with sterile PBS solution (2 500 L). Shortly after, their respective specimens were 
transferred to microdilution well plates containing YNB, in addition to the antifungal test, and 
then incubated at 37 C for 24 hours, under agitation of 75 rpm.  
Microdilution plates containing YNB broth added with antifungal agents, although without 
specimens and their respective biofilms developed in different phases, were used as sterility 
controls 2. All assays were systematically performed in triplicate. 
 
Bioactivity of the biofilm growth kinetics 
Growth kinetics of C. albicans biofilms against the specimens was monitored by the 
reduction assay of the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT), a semiquantitative measure of biofilms.24,25 
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Aliquots of 10 ml of saturated solutions (500 mg.L-1 in PBS solution) of XTT (XTT sodium 
salt, SIGMA Cat. # X4626, Sigma Chemical Co.) were produced, sterilized by filtration 
(Millipore Corporation, hydrophilic Durapore PVDF, 0.22 μm,  47 mm, Cat. # GVWP 047 
00), and stored at –70 C until the time of use. Prior to testing, a newly prepared menadione 
solution (10 mM in acetone; Crystalline Menadione, SIGMA Cat. # M5625, Sigma Chemical 
Co.) was added to the aliquots of the thawed XTT saturated solution (final menadione 
concentration equivalent to 1 M). This XTT-menadione solution was distributed into the 
microdilution well plates (48-well cell culture microplates, flat-bottom, Corning Inc., 
Corning, NY, USA) in aliquots of 200 L. 
After completing the development phases of the control biofilms or those treated with 
antifungal agents, the respective specimens were carefully washed twice with PBS solution, 
transferred to the microdilution plates containing the XTT-menadione solution, and statically 
incubated at 37C for 5 hours. Then, aliquots of 100 L of each well were gently transferred 
to microdilution plates (96-well cell culture microplates, Corning Inc., Corning, NY, USA) 
and the soluble formazan product was quantified by spectrophotometry at 492 nm (Thermo 
Scientific NanoDrop 2000c Spectrophotometer, Wilmington, DE, USA). 
 
Confocal Laser Scanning Microscope (CLSM) 
The growth kinetics of biofilms against the specimens was analyzed by Confocal 
Laser Scanning Microscope (LEICA TCS SP5 Microscope, Leica Microsystems, Wetzlar, 
Germany). The initial conditions of this assay were performed as previously described (see 
2.4 and 2.5). Preconditioning favorable to higher cellular metabolic activity (data obtained 
from 2.6), all times of the biofilm growth kinetics (1 ½, 8, 24, and 48h), and antifungal 
treatments (FLU, AB, and NYS: minimum concentration incapable of fully inhibiting 
metabolic activity) were used as inclusion criteria for the assay. 
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After these initial assays, specimens were washed 3 with 500 µL of PBS solution and fixed 
(lower portions) with instant adhesive (Loctite - Super Bonder, Henkel Ltda., São Paulo) in 
coverslips (18mm  18mm – KASVI/Olen, model k5-1818). Excess moisture from specimens 
was carefully removed by the contact between their lower portions and sterile filter paper 
(Whatman n3). Adhered cells and/or biofilms on the upper surfaces of specimens were 
carefully submerged in fluorescent dye solution (LIVE/DEAD BacLight Bacterial Viability 
Kit, Invitrogen, Cat. # L7007, Eugene, OR, USA) for 15 minutes and in PBS solution for 10 
seconds. With this method we can monitor cell viability regarding the cell membrane 
integrity. Therefore, cells with compromised membrane (non-viable) are visualized in red 
stain, whereas cells with intact membrane (viable) are visualized in green stain and, 
depending on the intensity of both dyes in overlapping images, non-viable cells are visualized 
in yellow stain. 
A chamber (chamber glass bottom dishes, BioImager, Cat. #100350, Vaughan, Ontario, 
Canada), with a polypropylene ring (13mm  3mm) adapted and fixed to the center, was used 
to support specimens fixed in the coverslip. This adaptation allowed each fixed specimen to 
remain submerged in PBS solution and without contact with the surface of the chamber, thus 
avoiding structural damage in the biofilm throughout analyses by inverted confocal laser 
scanning microscope. 
The cell viability (percentage of green pixels: viable cells; percentage of red/yellow pixels: 
non-viable cells), relative biomass of biofilm (PX    m   3m3 m nn   , where 
PX and m are units of measurements in pixels and micrometers, respectively; 1 m = 1.2933 
pixels or 1m3 = 1.089515 pixels) and thickness of the biofilm (µm) were evaluated by 
images captured in intervals of 1 µm and using the Leica LAS AF Lite software (LEICA, 
Wetzlar, Germany). The 3D reconstruction of the biofilm was made using the Fiji software, 
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version 2.0.0-RC-67/1.52 C (National Institutes of Health de Wayne Rasband, Bethesda, 
United States of America). 
 
Statistical analysis 
Semiquantitative data obtained from the XTT reduction assays, from the growth 
kinetics of C. albicans biofilms, were submitted to one-way analysis of variance (ANOVA), 
according to a factor scheme of 6  4  4 (time  surface  treatment) and the comparison of 
means by the Tukey test ( = 0.05), using the SAS software, version 9.2.  
The biofilm sessile minimum inhibitory concentration capable of reducing 50% (SMIC50) and 
80% (SMIC80) of the metabolic bioactivity was calculated by regression analysis, using the 
mean of absorbance values (492 nm) of the data of all preconditionings (PBS, AS, FBS, and 
AS+FBS). 
Biological (non-viable cells) and magnitude parameters (relative biomass and thickness) of 
the growth kinetics of C. albicans biofilms, under the influence of the adsorb film (FBS) and 
exposure to antifungal agents, were also subjected to one-way analysis of variance (ANOVA), 
according to a factor scheme of 4  4 (time  treatment) and comparison of means by Tukey 
test ( = 0.05), using the SAS software version 9.2. 
 
RESULTS 
Bioactivity of the biofilm growth kinetics 
The effects of treatments with antifungal agents (FLU, AB, NYS) on C. albicans 
biofilms, grown in the specimens during different development phases and preconditionings, 
were tested from the XTT reduction assay (Abs492nm). Test values in triplicate resulted in 
means that were statistically significant (p  0.05) and varied SMICs50-80 in all analyses 
performed. 
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Development of biofilms in the presence of FLU showed a reduction in metabolic activity 
according to the increase in concentration of antifungal agents [means with the same letter are 
not significantly different (p  0.05): 500 µg/mlH, 250 µg/mlG, 125 µg/mlF, 62.5 µg/mlE, 31.2 
µg/mlD, 15.6 µg/mlC, and 7.81 µg/mlB)], and therefore, there was no complete inhibition of 
bioactivity at the tested concentrations (Table 1 and Fig. 1). In preconditioning analyses, 
greatest bioactivities were recorded in the acquired films containing only FBS, followed by 
AS+FBS, AS, and PBS, respectively (Table 1 and Fig. 1). In the development phases of the 
biofilm under treatment with FLU, the period that featured the highest metabolic activity was 
the maturation phase (48h), followed by the initial (8h), adhesion (1 ½ h), and intermediate 
(24h) phases (Table 1 and Fig. 1). The biofilm sessile minimum inhibitory concentration of 
FLU was as follows (Fig. 2): 
 Adhesion phase (1 ½ h): SMIC50 corresponds to 15.625 g/ml; 
 Initial phase (8h): SMIC50 corresponds to 31.25 g/ml; 
 Intermediate phase (24h): SMIC50 corresponds to 31.25 g/ml; 
 Maturation phase (48h): SMIC50 and SMIC80 correspond to 125 and 500 g/ml, 
respectively. 
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Table 1. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida albicans 
biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb films and 
fluconazole.  
 
Treatment Time Preconditioning test systems 
 (hour) PBSD  ASC BFSA AS and BFSB 
  Mean SD Mean SD Mean SD Mean SD 
Growth control 1 ½ 0.3341 0.0156 0.3250 0.0103 0.3719 0.0109 0.3461 0.0190 
(YNB and yeast)A 8 0.3075 0.0014 0.3075 0.0014 0.3308 0.0100 0.3274 0.0058 
 24 0.3073 0.0032 0.3447 0.0177 0.3888 0.0091 0.3508 0.0033 
  48 0.3204 0.0225 0.3518 0.0330 0.3637 0.0248 0.3498 0.0182 
Sterility control 1 1 ½ 0.0466 0.0012 0.0473 0.0013 0.0449 0.0029 0.0485 0.0019 
(YNB)I 8 0.0456 0.0029 0.0501 0.0053 0.0494 0.0018 0.0522 0.0060 
  24 0.0484 0.0015 0.0482 0.0013 0.0485 0.0010 0.0474 0.0001 
  48 0.0479 0.0009 0.0479 0.0002 0.0476 0.0001 0.0477 0.0002 
Sterility control 2 1 ½ 0.0478 0.0002 0.0488 0.0011 0.0492 0.0016 0.0550 0.0042 
(YNB and 8 0.0478 0.0002 0.0488 0.0011 0.0492 0.0016 0.0550 0.0042 
Fluconazole 24 0.0478 0.0002 0.0488 0.0011 0.0492 0.0016 0.0550 0.0042 
500 µg/ml)I 48 0.0478 0.0002 0.0488 0.0011 0.0492 0.0016 0.0550 0.0042 
Fluconazole 1 ½C                 
7.8125 µg/mlB   0.1858 0.0048 0.2926 0.0068 0.2431 0.0132 0.1793 0.0008 
15.625 µg/mlC   0.1802 0.0074 0.1929 0.0063 0.2289 0.0140 0.1754 0.0030 
31.25 µg/mlD   0.1325 0.0084 0.1880 0.0079 0.2298 0.0182 0.1566 0.0010 
62.5 µg/mlE   0.1196 0.0014 0.1657 0.0056 0.2456 0.0260 0.1454 0.0049 
125 µg/mlF   0.1169 0.0037 0.1628 0.0137 0.2168 0.0158 0.1290 0.0035 
250 µg/mlG   0.1169 0.0022 0.1382 0.0137 0.2014 0.0083 0.1147 0.0055 
500 µg/mlH   0.1129 0.0041 0.1365 0.0040 0.1473 0.0174 0.1039 0.0022 
Fluconazole 8B                 
7.8125 µg/mlB   0.1847 0.0060 0.2412 0.0024 0.2680 0.0029 0.3002 0.0052 
15.625 µg/mlC   0.1661 0.0036 0.2093 0.0056 0.2304 0.0012 0.2774 0.0029 
31.25 µg/mlD   0.1567 0.0042 0.1397 0.0005 0.2198 0.0003 0.2410 0.0025 
62.5 µg/mlE   0.1359 0.0036 0.1370 0.0023 0.2180 0.0017 0.2158 0.0024 
125 µg/mlF   0.1268 0.0036 0.1260 0.0043 0.2169 0.0018 0.2049 0.0044 
250 µg/mlG   0.1168 0.0059 0.1199 0.0017 0.2149 0.0014 0.2044 0.0038 
500 µg/mlH   0.1053 0.0038 0.1183 0.0011 0.1984 0.0059 0.1974 0.0034 
Fluconazole 24D                 
7.8125 µg/mlB   0.1497 0.0118 0.2266 0.0133 0.3303 0.0140 0.3440 0.0041 
15.625 µg/mlC   0.1462 0.0128 0.1914 0.0024 0.3152 0.0058 0.2532 0.0060 
31.25 µg/mlD   0.1437 0.0141 0.1405 0.0011 0.2111 0.0024 0.1510 0.0153 
62.5 µg/mlE   0.1253 0.0082 0.1392 0.0023 0.1905 0.0029 0.1139 0.0059 
125 µg/mlF   0.1188 0.0049 0.1114 0.0021 0.1607 0.0086 0.1106 0.0012 
250 µg/mlG   0.1094 0.0028 0.1073 0.0005 0.1421 0.0086 0.1092 0.0002 
500 µg/mlH   0.1068 0.0007 0.1059 0.0001 0.1210 0.0062 0.1082 0.0001 
Fluconazole 48A                 
7.8125 µg/mlB   0.2913 0.0033 0.2679 0.0108 0.3260 0.0245 0.3171 0.0032 
15.625 µg/mlC   0.2579 0.0168 0.2217 0.0106 0.2636 0.0071 0.2990 0.0100 
31.25 µg/mlD   0.2355 0.0080 0.1823 0.0053 0.2536 0.0059 0.2883 0.0044 
62.5 µg/mlE   0.1811 0.0104 0.1702 0.0038 0.2431 0.0098 0.2602 0.0062 
125 µg/mlF   0.1390 0.0046 0.1360 0.0141 0.1506 0.0074 0.1342 0.0110 
250 µg/mlG   0.1361 0.0054 0.1160 0.0077 0.1370 0.0087 0.1297 0.0082 
500 µg/mlH   0.0956 0.0077 0.0903 0.0054 0.1107 0.0000 0.1183 0.0048 
Means with the same letter (A, B, C, D, E, F, G, H or I) are not significantly different (p  0.05). Shown are data from the 
controls growth (CG) and controls sterility 1 (SC1: YNB) and 2 (SC2: YNB+FLU) and different concentrations of 
fluconazole (7.81-500 µg/ml). SD, AS and BFS correspond to standard derivation, artificial saliva and bovine fetal serum, 
respectively. 
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Figure 1. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of 
adsorb films and fluconazole: treatment (A), surface (B), and time (C). AS and FBS correspond to 
artificial saliva and bovine fetal serum, respectively. Direct test (sterile PBS solution). Means with the 
same letter (A, B, C, D, E, F, G, H, or I) are not significantly different (p  0.05). 
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Figura 2 Biofilm sessile minimum Inhibitory concentration (SMIC) profiles of fluconazole, 
obtained from the growth kinetics of Candida albicans biofilms against specimens (vinyl 
polysiloxane prosthesis rebase) and under the influence of adsorb films. 
 
 
 
 
The exposure of biofilm formation kinetics to the treatment with AB showed that bioactivity 
decreased with the increase of antifungal concentration [means with the same letter are not 
significantly different (p  0.05):: 500 and 250 µg/mlF, 125 and 62.5 µg/mlE, 31.2 µg/mlD, 
15.6 µg/mlC, and 7.81 µg/mlB)], and therefore, there was no complete inhibition of bioactivity 
at the tested concentrations (Table 2 and Fig. 3). Preconditioning with FBS presented the 
highest bioactivity among the tested acquired films, and metabolic activity of the other 
analyzed films (AS, AS+FBS, and PBS) did not present statistical differences in the XTT 
colorimetric assay (Table 2 and Fig. 3). Metabolic rates had a significant increase when 
associated with the phases of biofilm development in the treatment with AB, and the 
maturation phase (48h) was the one that presented the highest bioactivity, followed by 
intermediate (24h), initial (8h), and adhesion (1 ½ h) phases, respectively (Table 2 and Fig. 3). 
The biofilm sessile minimum inhibitory concentration of AB was as follows (Fig. 4): 
 Adhesion phase (1 ½ h): SMIC50-80 corresponds to 7.8125 g/ml; 
 Initial phase (8h): SMIC50-80 corresponds to 7.8125 g/ml; 
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 Intermediate phase (24h): SMIC50-80 corresponds to 7.8125 g/ml; 
 Maturation phase (48h): SMIC50 and SMIC80 correspond to 7.8125 and 250 g/ml, 
respectively. 
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Table 2. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb 
films and amphotericin B.  
 
Treatment Time Preconditioning test systems 
 (hour) PBSB  ASB BFSA AS and BFSB 
  Mean SD Mean SD Mean SD Mean SD 
Growth control 1 ½ 0.3341 0.0156 0.3250 0.0103 0.3719 0.0109 0.3461 0.0190 
(YNB and yeast)A 8 0.3075 0.0014 0.3075 0.0014 0.3308 0.0100 0.3274 0.0058 
 24 0.3073 0.0032 0.3447 0.0177 0.3888 0.0091 0.3508 0.0033 
  48 0.3204 0.0225 0.3518 0.0330 0.3637 0.0248 0.3498 0.0182 
Sterility control 1 1 ½ 0.0466 0.0012 0.0473 0.0013 0.0449 0.0029 0.0485 0.0019 
(YNB)H 8 0.0456 0.0029 0.0501 0.0053 0.0494 0.0018 0.0522 0.0060 
  24 0.0484 0.0015 0.0482 0.0013 0.0485 0.0010 0.0474 0.0001 
  48 0.0479 0.0009 0.0479 0.0002 0.0476 0.0001 0.0477 0.0002 
Sterility control 2 1 ½ 0.0560 0.0004 0.0560 0.0029 0.0552 0.0035 0.0555 0.0026 
(YNB and 8 0.0560 0.0004 0.0560 0.0029 0.0552 0.0035 0.0555 0.0026 
amphotericin B 24 0.0560 0.0004 0.0560 0.0029 0.0552 0.0035 0.0555 0.0026 
500 µg/ml)G 48 0.0560 0.0004 0.0560 0.0029 0.0552 0.0035 0.0555 0.0026 
Amphotericin B 1 ½D                 
7.8125 µg/mlB   0.0462 0.0012 0.0476 0.0019 0.0478 0.0017 0.0498 0.0002 
15.625 µg/mlC   0.0485 0.0019 0.0473 0.0011 0.0494 0.0017 0.0496 0.0002 
31.25 µg/mlD   0.0468 0.0010 0.0480 0.0032 0.0466 0.0008 0.0493 0.0004 
62.5 µg/mlE   0.0450 0.0018 0.0469 0.0006 0.0464 0.0010 0.0511 0.0005 
125 µg/mlE   0.0496 0.0005 0.0507 0.0002 0.0497 0.0004 0.0504 0.0002 
250 µg/mlF   0.0484 0.0010 0.0506 0.0002 0.0494 0.0002 0.0509 0.0005 
500 µg/mlF   0.0544 0.0021 0.0541 0.0008 0.0538 0.0011 0.0546 0.0015 
Amphotericin B 8C                 
7.8125 µg/mlB   0.0880 0.0021 0.0850 0.0022 0.0758 0.0005 0.0773 0.0010 
15.625 µg/mlC   0.0752 0.0003 0.0835 0.0057 0.0714 0.0005 0.0646 0.0023 
31.25 µg/mlD   0.0558 0.0020 0.0602 0.0007 0.0634 0.0046 0.0524 0.0018 
62.5 µg/mlE   0.0595 0.0016 0.0528 0.0009 0.0532 0.0031 0.0519 0.0015 
125 µg/mlE   0.0678 0.0011 0.0558 0.0036 0.0538 0.0013 0.0496 0.0002 
250 µg/mlF   0.0553 0.0011 0.0568 0.0003 0.0547 0.0002 0.0546 0.0005 
500 µg/mlF   0.0555 0.0015 0.0579 0.0002 0.0590 0.0022 0.0602 0.0007 
Amphotericin B 24B                 
7.8125 µg/mlB   0.1486 0.0014 0.1056 0.0016 0.0912 0.0056 0.0823 0.0016 
15.625 µg/mlC   0.1147 0.0032 0.0902 0.0024 0.0895 0.0023 0.0808 0.0005 
31.25 µg/mlD   0.1052 0.0044 0.0845 0.0026 0.0861 0.0032 0.0805 0.0004 
62.5 µg/mlE   0.0865 0.0029 0.0757 0.0024 0.0847 0.0007 0.0752 0.0005 
125 µg/mlE   0.0801 0.0033 0.0733 0.0025 0.0798 0.0059 0.0729 0.0003 
250 µg/mlF   0.0630 0.0048 0.0702 0.0013 0.0746 0.0015 0.0655 0.0041 
500 µg/mlF   0.0620 0.0056 0.0606 0.0011 0.0722 0.0013 0.0568 0.0002 
Amphotericin B 48A                 
7.8125 µg/mlB   0.1492 0.0058 0.1700 0.0043 0.2147 0.0019 0.2154 0.0316 
15.625 µg/mlC   0.1388 0.0058 0.1528 0.0015 0.1544 0.0055 0.1655 0.0036 
31.25 µg/mlD   0.1282 0.0008 0.1429 0.0035 0.1346 0.0055 0.1356 0.0029 
62.5 µg/mlE   0.1194 0.0065 0.1228 0.0017 0.1207 0.0102 0.1207 0.0055 
125 µg/mlE   0.1046 0.0040 0.1067 0.0035 0.1205 0.0127 0.1109 0.0001 
250 µg/mlF   0.0997 0.0076 0.0834 0.0034 0.1087 0.0004 0.1066 0.0018 
500 µg/mlF   0.0781 0.0040 0.0749 0.0012 0.1029 0.0002 0.0917 0.0006 
Means with the same letter (A, B, C, D, E, F, G or H) are not significantly different (p  0.05). Shown are data from the 
controls growth (CG) and controls sterility 1 (SC1: YNB) and 2 (SC2: YNB+AB) and different concentrations of 
amphotericin B (7.81-500 µg/ml). SD, AS and BFS correspond to standard derivation, artificial saliva and bovine fetal serum, 
respectively. 
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Figure 3. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of 
adsorb films and amphotericin B: treatment (A), surface (B), and time (C). AS and FBS correspond to 
artificial saliva and bovine fetal serum, respectively. Direct test (sterile PBS solution). Means with the 
same letter (A, B, C, D, E, F, G, or H) are not significantly different (p  0.05). 
 
32 
 
 
Figure 4. Biofilm sessile minimum Inhibitory concentration (SMIC) profiles of amphotericin 
B obtained from the growth kinetics of Candida albicans biofilms against specimens (vinyl 
polysiloxane prosthesis rebase) and under the influence of adsorb films. 
 
 
 
 
Treatment with NYS resulted in the inhibition of metabolic activity (p  0.05) from 15.6 
µg/ml, considering the sterility control 1 (YNB), or from 62.5 µg/ml, considering the sterility 
control 2 (YNB and nystatin) (Table 3 and Fig. 5). Preconditioning tests of the specimens 
showed that there was bioactivity regardless of FBS, AS, and AS+FBS (Table 3 and Fig. 5). 
Biofilm development assays in treatment with NYS showed a higher metabolic activity in the 
maturation phase (48h), followed by intermediate (24h), initial (8h), and adhesion (1 ½ h) 
phases (Table 3 and Fig. 5). The biofilm sessile minimum inhibitory concentration of NYS 
was as follows (Fig. 6): 
 Adhesion phase (1 ½ h): SMIC50-80 and SMIC100 correspond to 7.8125 and 15.625 g/ml, 
respectively; 
 Initial phase (8h): SMIC50-80 corresponds to 7.8125 g/ml; 
 Intermediate phase (24h): SMIC50-80 corresponds to 7.8125 g/ml; 
 Maturation phase (48h): SMIC50 and SMIC80 correspond to 7.8125 and 62.5 g/ml, 
respectively. 
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Table 3. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida albicans 
biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb films and 
nystatin.  
 
Treatment Time Preconditioning test systems 
 (hour) PBSB  ASAB BFSA AS and BFSAB 
  Mean SD Mean SD Mean SD Mean SD 
Growth control 1 ½ 0.3341 0.0156 0.3250 0.0103 0.3719 0.0109 0.3461 0.0190 
(YNB and yeast)A 8 0.3075 0.0014 0.3075 0.0014 0.3308 0.0100 0.3274 0.0058 
 24 0.3073 0.0032 0.3447 0.0177 0.3888 0.0091 0.3508 0.0033 
  48 0.3204 0.0225 0.3518 0.0330 0.3637 0.0248 0.3498 0.0182 
Sterility control 1 1 ½ 0.0466 0.0012 0.0473 0.0013 0.0449 0.0029 0.0485 0.0019 
(YNB)CDE 8 0.0456 0.0029 0.0501 0.0053 0.0494 0.0018 0.0522 0.0060 
  24 0.0484 0.0015 0.0482 0.0013 0.0485 0.0010 0.0474 0.0001 
  48 0.0479 0.0009 0.0479 0.0002 0.0476 0.0001 0.0477 0.0002 
Sterility control 2 1 ½ 0.0477 0.0012 0.0529 0.0038 0.0499 0.0042 0.0491 0.0024 
(YNB and 8 0.0477 0.0012 0.0529 0.0038 0.0499 0.0042 0.0491 0.0024 
nystatin 24 0.0477 0.0012 0.0529 0.0038 0.0499 0.0042 0.0491 0.0024 
500 µg/ml)E 48 0.0477 0.0012 0.0529 0.0038 0.0499 0.0042 0.0491 0.0024 
Nystatin 1 ½C                 
7.8125 µg/ml   0.0540 0.0032 0.0499 0.0013 0.0436 0.0021 0.0508 0.0006 
15.625 µg/ml   0.0449 0.0004 0.0465 0.0018 0.0442 0.0030 0.0504 0.0002 
31.25 µg/ml   0.0453 0.0020 0.0463 0.0001 0.0445 0.0030 0.0489 0.0012 
62.5 µg/ml   0.0440 0.0011 0.0459 0.0006 0.0430 0.0001 0.0472 0.0001 
125 µg/ml   0.0440 0.0007 0.0461 0.0006 0.0438 0.0019 0.0476 0.0010 
250 µg/ml   0.0440 0.0013 0.0461 0.0000 0.0422 0.0000 0.0476 0.0011 
500 µg/ml   0.0429 0.0006 0.0461 0.0010 0.0419 0.0004 0.0466 0.0006 
Nystatin 8C                 
7.8125 µg/mlB   0.0632 0.0033 0.0762 0.0017 0.0682 0.0005 0.0654 0.0020 
15.625 µg/mlBC   0.0618 0.0017 0.0634 0.0027 0.0660 0.0038 0.0650 0.0050 
31.25 µg/mlBCD   0.0482 0.0004 0.0557 0.0011 0.0540 0.0017 0.0525 0.0004 
62.5 µg/mlBCDE   0.0480 0.0004 0.0556 0.0011 0.0526 0.0017 0.0508 0.0004 
125 µg/mlCDE   0.0479 0.0003 0.0548 0.0001 0.0485 0.0002 0.0495 0.0005 
250 µg/mlCDE   0.0479 0.0003 0.0547 0.0001 0.0485 0.0002 0.0481 0.0005 
500 µg/mlDE   0.0478 0.0004 0.0543 0.0003 0.0480 0.0002 0.0475 0.0001 
Nystatin 24B                 
7.8125 µg/mlB   0.1030 0.0006 0.1056 0.0024 0.1056 0.0018 0.1086 0.0002 
15.625 µg/mlBC   0.0851 0.0028 0.0909 0.0007 0.0863 0.0047 0.0819 0.0039 
31.25 µg/mlBCD   0.0820 0.0112 0.0646 0.0037 0.0662 0.0045 0.0641 0.0010 
62.5 µg/mlBCDE   0.0736 0.0044 0.0628 0.0019 0.0615 0.0013 0.0595 0.0016 
125 µg/mlCDE   0.0643 0.0042 0.0580 0.0056 0.0590 0.0005 0.0559 0.0018 
250 µg/mlCDE   0.0558 0.0018 0.0574 0.0064 0.0561 0.0024 0.0545 0.0020 
500 µg/mlDE   0.0553 0.0025 0.0504 0.0004 0.0541 0.0029 0.0517 0.0004 
Nystatin 48A                 
7.8125 µg/mlB   0.1120 0.0011 0.1118 0.0012 0.1213 0.0068 0.1163 0.0027 
15.625 µg/mlBC   0.1093 0.0014 0.1109 0.0001 0.1114 0.0008 0.1156 0.0035 
31.25 µg/mlBCD   0.1067 0.0003 0.1092 0.0007 0.1108 0.0001 0.1120 0.0022 
62.5 µg/mlBCDE   0.1031 0.0051 0.1073 0.0008 0.1094 0.0016 0.1051 0.0027 
125 µg/mlCDE   0.0904 0.0063 0.0994 0.0040 0.1078 0.0017 0.0965 0.0021 
250 µg/mlCDE   0.0776 0.0011 0.0953 0.0046 0.1001 0.0011 0.0916 0.0004 
500 µg/mlDE   0.0729 0.0023 0.0813 0.0002 0.0941 0.0051 0.0830 0.0033 
Means with the same letter (A, B, C, D or E) are not significantly different (p  0.05). Shown are data from the controls 
growth (CG) and controls sterility 1 (SC1: YNB) and 2 (SC2: YNB+NYS) and different concentrations of nystatin (7.81-500 
µg/ml). SD, AS and BFS correspond to standard derivation, artificial saliva and bovine fetal serum, respectively. 
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Figure 5. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of 
adsorb films and nystatin: treatment (A), surface (B), and time (C). AS and FBS correspond to artificial 
saliva and bovine fetal serum, respectively. Direct test (sterile PBS solution). Means with the same letter 
(A, B, C, D, or E) are not significantly different (p  0.05). 
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Figure 6. Biofilm sessile minimum Inhibitory concentration (SMIC) profiles of fluconazole, 
amphotericin B and nystatin obtained from the growth kinetics of Candida albicans biofilms 
against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb 
films. 
 
 
 
 
 
Tree-dimensional structure of biofilm 
 Confocal Laser Scanning Microscope (CLSM) analyses were performed to relatively 
determine the biological (non-viable cells) and magnitude (relative biomass and thickness) 
parameters in the growth kinetics of Candida albicans biofilms (1 ½, 8, 24, and 48h) against 
specimens (vinyl polysiloxane rebase prosthesis) and exposure to antifungal agents. For these 
assays, the preconditioning deemed favorable to the higher cellular metabolic activity was 
FBS, whereas the antifungal concentration (FLU, AB, and NYS) considered minimally 
desirable and unable to fully inhibit the cellular metabolic activity was 10 g/ml 10 g/ml 
([FLU]8h  SMIC50; SMIC50  [AB]8h  SMIC100; SMIC50  [NYS]8h  SMIC100), as 
previously determined by the XTT reduction assay. 
According to conditions established in this assay, treatments with antifungal agents FLU, AB, 
and NYS (identical concentrations) had no statistical differences (p  0.05), neither for 
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biological parameter (percentage of non-viable cells) nor for magnitude parameters (relative 
biomass and thickness) of the growth kinetics of C. albicans biofilms against the specimens. 
Among the development phases of C. albicans biofilms against specimens and exposure to 
antifungal agents, there were no statistically significant variations (p  0.05) considering the 
biological parameters (percentage of non-viable cells). However, significant variations (p  
0.05) were observed between these phases considering both magnitude parameters, either by 
the exposure or not to antifungal agents [i.e., relative biomass (m3) and thickness (µm) of 
adherent cells and biofilms were time-dependent (p  0.05)] (Table 4; Fig. 7 and Fig. 8). 
 
Table 4. Biological parameters (non-viable cells) and magnitude parameters (relative biomass and thickness) 
in the growth kinetics of C. albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and 
under the influence of adsorb film (FBS) and antifungal agents (10 g/ml: FLU, AB, and NYS), obtained 
from Confocal Laser Scanning Microscope (CLSM) analysis. Data generated by Leica LAS AF Lite software 
(LEICA, Wetzlar, Germany).  
 
Treatment Non-viable cells (%)* 
 1½hA 8hA 24hA 48hA 
AbsentB 0.001 9.601 14.136 47.937 
FluconazoleAB 55.248 45.084 44.218 36.927 
Amphotericin BAB 50.865 36.064 54.927 43.739 
NystatinA 55.680 59.440 51.511 44.854 
Treatment Relative biomass of biofilm (µm3) 
 1½hB 8hAB 24hA 48hA 
AbsentA 154.800 178.914 181.303 220.361 
FluconazoleA 84.125 214.148 233.008 220.216 
Amphotericin BA 88.604 92.745 214.947 216.097 
NystatinA 87.987 95.007 233.410 222.080 
Treatment Thickness of the biofilm (µm) 
 1½hC 8hBC 24hB 48hA 
AbsentA 33 42 60 123 
FluconazoleA 32 39 62 86 
Amphotericin BA 35 42 54 114 
NystatinA 32 44 63 112 
* Cells with a compromised membrane that are deemed dead or dying. 
Values with the same letter (A, B, or C) are not significantly different (p  
0.05). 
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Figure 7. Biological parameters (non-viable cells) and magnitude parameters (relative biomass 
and thickness) in the growth kinetics of C. albicans biofilms against specimens (vinyl 
polysiloxane prosthesis rebase) and under the influence of adsorb film (FBS) and antifungal 
agents (10 g/ml: FLU, AB, and NYS), obtained from Confocal Laser Scanning Microscope 
(CLSM) analyses. Values with the same letter (A, B, and C) p  0.05 (are not significantly 
different). 
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Figure 8. CLSM images in different growth periods of Candida albicans biofilms against 
specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb film (FBS) 
and antifungal agents (FLU, AB, and NYS: 10 g/ml). 3D images generated by the Fiji v.2.0.0-
rc- 67/1.52c software (National Institutes of Health de Wayne Rasband, Bethesda, United States 
of America). 
 
1½ – Adhesion phase 
    
 
8h – Initial phase 
    
 
24h – Intermediate phase 
    
 
48h – Maturation phase 
    
 
 
DISCUSSION 
 In our study, we evaluated the growth kinetics of C. albicans biofilms against 
specimens obtained from a prosthetic rebase (vinyl polysiloxane) and influenced by four 
adsorb films and three antifungal agents commonly used in the clinical therapy of stomatitis 
caused by Candida species. The prosthesis rebase (vinyl polysiloxane) proved to be prone to 
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colonization and formation of biofilms by C. albicans, especially in biological 
preconditioning systems. Growth kinetics of C. albicans biofilms showed dose-dependent 
antifungal resistance, thus corroborating several data previously described in the literature on 
the resistance/tolerance of biofilms to antifungal agents. 3,19,27,28,29 
Treatment of the different development phases of C. albicans biofilms with FLU showed 
partial effectiveness as follows: dose-dependent (i.e., reduced bioactivity from 7.8125 to 500 
g/ml), surface-dependent (i.e., preconditioned bioactivity in FBS  AS+FBS  AS  PBS), 
and time-dependent (i.e., bioactivity at 48h  8h  1½h  24h). FLUE showed a statistically 
higher capacity of action on the biofilm at the intermediate phase (24h). By regression 
analysis, SMIC50 of FLU varied (15.625–125 g/ml) between periods of biofilm formation 
kinetics, whereas SMIC80 was observed only at the maturation phase (500 g/ml). These 
concentrations represent values far above (7.8) those recommended for planktonic cells 
resistant to FLU (64 g/ml).26 
Treatment of the different development phases of C. albicans biofilms with AB showed 
partial effectiveness as follows: dose-dependent (i.e., reduced bioactivity from 7.8125 to 500 
g/ml), surface-dependent (i.e., preconditioned bioactivity in FBS  AS+FBS = AS = PBS), 
and time-dependent (i.e., bioactivity at 48h  24h  8h  1½h). AB showed a statistically 
higher capacity of action in the adhesion phase (1 ½ h). By regression analysis, the SMIC50 of 
AB did not vary (7.8125 g/ml) between periods of the biofilm formation kinetics, whereas 
the SMIC80 varied (7.8125–250 g/ml) between the periods. These concentrations represent 
values far above (500) those recommended for planktonic cells resistant to AB (1 g/ml).26 
The treatment of the different developmental phases of C. albicans biofilms with NYS 
showed statistically significant inhibition from 15.625 µg/ml (75.9 IU/mg) or 62.5 µg/ml 
(303.5 IU/mg) (depending on the experimental criterion adopted: sterility control 1 or 2) and 
partial effectiveness as follows: dose-dependent from higher antifungal concentrations (i.e., 
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reduced bioactivity from 31.25 or 125 to 500 g/ml), surface-independent (i.e., 
preconditioned bioactivity in FSB = AS+FSB = AS = PBS, but FSB  PBS), and time-
dependent (i.e., bioactivity at 48h  24h  8h = 1½h). These NYS concentrations represent 
values far above (3.9-125 to 15.6-500) those recommended for planktonic cells (0.125 and 
4 μg/mL; 0.61 and 19.43 IU).30 The NYS presented statistically higher capacity of action on 
the biofilm at the initial and adhesion phases (8h and 1 ½ h). By regression analysis, the 
SMIC100 of NYS was observed at the adhesion phase (1½h: 15.625 g/ml), whereas SMIC50 
did not vary (7.8125 g/ml) between periods of the biofilm formation kinetics, and SMIC80 
varied (7.8125–62.5 g/ml) between the periods. Recommended doses of nystatin for topical 
use range from 200,000 to 600,000 IU (41.18–123.54 mg) for children and adults; and from 
100,000 to 200,000 IU (20.59–41.18 mg) for newborns and children, with therapeutic 
prescription from 1 to 4 weeks.31 Our findings (75.9 IU/mg or 303.5 IU/mg) potentially 
corroborate the success of the clinically superficial antifungal prophylaxis or therapy in 
possible cases of the prescription of nystatin for patients using dental prostheses with 
stomatitis caused by Candida species susceptible or resistant to other antifungal agents, 
especially C. albicans. 
Confocal Laser Scanning Microscope (CLSM) proved to be an effective tool in structural and 
feasibility analyses of biofilms.24,32,33 In our study, according to the conditions established in 
the CLSM assay, treatments with FLU, AB, and NYS at the same concentrations equally 
exerted effects on the biological parameters (percentage of non-viable cells) and on 
magnitude parameters (relative biomass and thickness) of the growth kinetics of C. albicans 
biofilms against specimens. We did not find variations between development phases of the 
biofilms and exposure to antifungal agents regarding biological parameters (percentage of 
non-viable cells). On the other hand, we observed variations between the development phases 
of biofilms in the magnitude parameters, being exposed or not to antifungal agents, namely 
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the relative biomass and the time-dependent thickness (i.e., higher in volume and height in the 
advanced phases of biofilm formation). Such add important information to the models 
proposed for studies on biofilms involving C. albicans, in addition to corroborating other 
studies on the kinetics of biofilms against surfaces of dental materials [e.g., 
polymethylmethacrylate (PMMA), silicon- and resin-based materials] under the influence of 
adsorb films and exposure to antifungal agents and antiseptics.28,32,34,35,36,37 
Adhesion (30-min phase) of C. albicans cells (clinical isolates D1.2 and D2.2) to polystyrene 
surfaces (microdilution plates) was significantly higher at conditions of serum 
preconditioning of surfaces (i.e., 244% increase and 220% for isolates D1.2 and D2.2, 
respectively, from the control group), when compared with surfaces with salivary adsorb 
films and without preconditioning (control group). At the initial time (4 hours) of 
development of surface biofilms with serum films, this increase was 132% (D1.2) and 130% 
(D2.2) compared with the respective control groups, while biofilms with 24-hour 
development time did not feature significant differences between systems with and without 
adsorb films. On the other hand, initial adherence levels (30 min) in salivary films increased 
by 31% (D1.2) and 9% (D2.2) compared with the respective control groups; however, there 
were no significant differences between the other times (4 and 24 hours).3 The development 
of C. albicans biofilms (SC5314) was also studied using five different polystyrene 
microtitration plates [Greiner Bio-One (ref. 655090 and ref. 655101), CoStar® (ref. 3370), 
VWR International (ref. 10062-900) and TPP Techno Plastic Products AG (ref. 92096)], from 
surfaces with and without serum films (fetal bovine serum – FBS) and different inoculum 
concentrations (OD600 = 0.1; 0.2; 0.5; 1; and 2). These biofilms were thicker in the presence 
of FBS, indicating that interactions between FBS and the surface of the plates favor the 
cellular and structural fixation of the biofilm on the tested surfaces.36 Additionally, the 
increase in the adhesion of C. albicans planktonic cells to serum-preconditioned surfaces may 
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be due to the presence of serum proteins (e.g., albumin) that increase the binding sites and the 
adhesion efficiency.38 
C. albicans biofilms (GDH-2346/denture stomatitis; M-61/intravascular catheter) under 
development (i.e., including intermediate and maturation phases), against 
polymethylmethacrylate discs and silicone elastomer preconditioned in FBS, and featuring a 
certain degree of antifungal and antiseptic resistance, were previously reported: amphotericin 
B (0.5–8 μg/ml), fluconazole (1–128 μg/ml), nystatin (8–32 μg/ml), and chlorhexidine (16–
256 μg/ml).35 Authors of a study on the growth kinetics of biofilms against polystyrene 
surfaces (microdilution plates), involving different C. albicans strains (SC5314, 3153A, 
ATCC 64550, ATCC 64558, ATCC 76615, ATCC 90028, and ATCC 90029) and exposure to 
antifungal agents fluconazole and amphotericin B, also demonstrated high antifungal 
resistance and variations in the biofilm sessile minimum inhibitory concentrations: 
fluconazole – SMIC50 and SMIC80 1024 μg/ml; amphotericin B – SMIC50 from 0.25 to 0.5 
μg/ml and SMIC80 from 1 to 8 μg/ml 39. In another assay of antifungal sensitivity of C. 
albicans biofilms (SC5314 and seven clinical isolates), researchers reported highly resistant 
profiles associated with varied SMIC: SMIC50 ˃1024 µg/ml and SMIC80 ˃1024 µg/ml for 
fluconazole treatment; SMIC50 from 0.25 to 1 µg/ml and SMIC80 for amphotericin B; and 
SMIC50 from 0.03125 to 0.125µg/ml and SMIC80 from 0.03125 to 0.25 µg/ml for 
caspofungin.37 Mature biofilms (48h) of C. albicans (ATCC 90028), developed against 
surfaces of polymethylmethacrylate-based resin discs (PMMA), were treated with fluconazole 
and nystatin at concentrations of 10 and 100, corresponding to MIC values of planktonic cells 
(i.e., MICs of 0.5 and 2 µg/ml for fluconazole and nystatin, respectively). For fluconazole, 
there was no statistically significant reduction in the metabolic activities of biofilms at the 
tested concentrations. However, treatment with nystatin showed a reduction in metabolic 
bioactivity of biofilms, of 80% and 95% for concentrations of 10 and 100 respectively, 
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without structural influences on the biofilm architecture.32 The antifungal action of five 
antimicrobial agents (nystatin, chlorhexidine, ketoconazole, miconazole, and itraconazole), 
incorporated into two different types of dental materials (Trusoft and Softone), were analyzed 
during the development of the C. Albicans biofilm (SC5314) in periods of 24h, 48h, 7 days, 
and 14 days. In the analyzed periods, there was a reduction of 90% in fungal growth for all 
drugs and in both dental materials tested. Concentrations of drugs incorporated into the dental 
materials were 32 µg/ml for nystatin, 64 µg/ml for chlorhexidine, 128 µg/ml for ketoconazole, 
and 256 µg/ml for miconazole and itraconazole, and higher concentrations did not account for 
a significant reduction. This inhibitory effect was demonstrated by qualitative analyses of 
viable and non-viable cells from Confocal Laser Scanning Microscope (CLSM) images, using 
both incorporated dental materials with different antimicrobial agents and in two periods (24h 
and 14 days).34 
Many of these findings corroborate our data found in this study. We may infer that variations 
of SMICs values of C. albicans biofilms considering the exposures to antifungal agents, 
observed in the literature and presented in our study, could be partly explained by the assay 
conditions (e.g., development phases of the biofilm, types of surfaces, and size of the 
specimen, type of culture media, variations in test volumes and others), and by genetically 
intrinsic characteristics of C. albicans strains. The growth kinetics of C. albicans biofilm is 
directly related to the increase in metabolic activity, structural architecture, and biomass, and 
its interaction with the adsorb film of surfaces, characteristics which also exert important 
influence on the mechanisms of antifungal resistance and other inhibitory compounds. 
 
CONCLUSION 
 Overall, FLU presents dose-dependent, surface-dependent, and time-dependent partial 
effectiveness, especially in the intermediate phase of the development of C. albicans biofilms. 
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SMIC of FLU represents a resistance value above (7.8) of the MIC of planktonic cells (64 
g/ml) and, therefore, C. albicans biofilms in the formation process are potently resistant to 
FLU. AB presents dose-dependent, surface-dependent, and time-dependent partial 
effectiveness, especially in the adhesion phase of the development of C. albicans biofilms. 
SMIC of AB represents a resistance value above (500) of the MIC of planktonic cells (1 
g/ml) and, therefore, C. albicans biofilms in the formation process are potently resistant to 
AB. NYS presents dose-dependent, surface-dependent, and time-dependent inhibition, 
especially in the adhesion phase of the development of C. albicans biofilms. SMIC of NYS 
represents a value above (3.9-125 to 15.6-500) of the MIC of planktonic and clinical cells 
(0.125 and 4 μg/mL; 0.61 and 19.43 IU) and, therefore, C. albicans biofilms in the formation 
process are more resistant to NYS when compared with planktonic cells. However, it is 
inferred that nystatin prescription for patients using dental prostheses with stomatitis caused 
by Candida species resistant or susceptible to other antifungals, especially C. albicans, will 
potentially corroborate the success of clinically superficial antifungal therapy.  
Preconditioning with FBS significantly contributes to the growth kinetics of C. albicans 
biofilms against the specimens, as a result of the higher metabolic activities even under the 
influence of the exposure to antifungal agents FLU and AB, except for the influence of NYS 
(i.e., its effective action is independent of adsorb films generated from FBS, AS or AS+FBS). 
Exposure to antifungal agents FLU, AB, and NYS in identical concentrations also exerts an 
effect on biological (percentage of non-viable cells) and magnitude (relative biomass and 
thickness) parameters during the growth kinetics of C. Albicans biofilms against test 
specimens. This phenomenon implies that viable cells (i.e., marked with LIVE/DEAD™) do 
not necessarily present metabolic activities (i.e., by the XTT assay), since bioactivity of the 
biofilm growth kinetics is also influenced by the type and concentrations of antifungal agents. 
Variations in the magnitude parameters (relative biomass and thickness) depend on the 
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development phases of C. albicans biofilms against the specimens, whereas the biological 
parameters (percentage of non-viable cells) tend to be constant throughout the formation 
kinetics of C. albicans biofilms. Therefore, the maintenance of viable cells of C. albicans, 
under adverse conditions, relies on dynamic and differentiated architectural structures 
throughout the biofilm formation kinetics. 
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Abstract 
Objective: This study aimed to evaluate the anti-biofilm effects of hydroalcoholic (FEHi) and 
dry (DEHi) extracts of H. impetiginosus bark using in vitro test models and Candida albicans 
biofilm development kinetics on specimen surfaces (prosthetic relining, vinyl polysiloxane) and 
under the influence of adsorbed films. Methods: Specimens (dental prosthesis reline material, 
Silagum-Comfort Soft Relining®) were submerged in preconditioning systems: PBS, artificial 
saliva (AS), fetal bovine serum (FBS), and AS+FBS (1:1). Newly cultivated planktonic cells 
were incubated in microdilution plates, containing the specimens and appropriate medium, for 
1½h (adhesion: PBS), 8h (initial: YNB), 24h (intermediate: YNB), and 48h (maturation: YNB). 
The biofilm sessile minimum inhibitory concentration (SMIC) was obtained by the broth 
microdilution method (from 3.125 to 200 mg/ml). Bioactivity of biofilms was monitored by 
XTT assay. Cell viability, relative biomass of biofilm (mm3), and biofilm thickness (µm) were 
evaluated using a confocal laser scanning microscope (CLSM). Ultrastructural morphology was 
analyzed using a scanning electron microscope (SEM). Results: FBS favorably influenced the 
development and resistance of biofilm in all situations analyzed in this study. On average, FEHi 
showed inhibition of metabolic activities 100 mg/ml (stronger action in 1½h and 8h). SMIC80 
of FEHi gradually increased throughout the biofilm development (SMIC80 of 3.125, 6.25 and 
200 mg/ml for the adhesion phase, and initial, intermediate and maturation phases, 
respectively). In general, DEHi showed partial inhibition of metabolic activities (stronger action 
in 8h and 24h). SMIC80 of DEHi was not observed at the concentrations tested in this study. 
FEHi and DEHi act equally on the biological parameter (percentage of non-viable cells) and 
magnitude parameters (relative biomass and thickness) of C. albicans biofilms. Biofilm 
thickness was greater in the maturation phase, while the percentages of non-viable cells and 
relative biomass of biofilm were invariable throughout the biofilm development. FEHi and 
DEHi produced variable effects in terms of dimorphism, microbial volume and microbial 
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population density, especially in the adhesion and initial phases of C. albicans biofilm 
development. Conclusion: In conclusion, FEHi and DEHi have dose-, surface- and time-
dependent effectiveness. However, FEHi has greater anti-biofilm effect, suggesting its potential 
application to the development of new drugs and related products, especially for oral or 
prosthetic prophylaxis and antisepsis for C. albicans anti-biofilm, either as mouthwash or 
dentifrice. Thickness variations are time-dependent, while percentages of non-viable cells and 
relative biomass of biofilm are time-independent, probably due to the potentially low anti-
biofilm action of FEHi and DEHi. Ultrastructural morphological characteristics are dependent 
on H. impetiginosus extract and development phases of C. albicans biofilms, suggesting 
differences in the phytochemical composition of both extracts. 
 
Introduction 
Candida albicans is the main etiological agent of denture stomatitis, affecting around 
35% to 75% of denture wearers, depending on the population. Candida albicans treatment 
should be based on the multiple factors of this infection (i.e., replacement of the old prosthesis, 
antifungal therapy, and prophylactic measures of oral hygiene), but the use of soft and resilient 
materials to improve the adaptation and recovery of tissue exposed to prosthesis is more 
susceptible to colonization, formation and development of C. albicans biofilm on prosthetic 
surfaces, increasing the risk of infection (Cavalcanti et al. 2016; Bassi & Boriollo 2019). 
The formation of C. albicans biofilm is the main factor of virulence, since it consists of 
a complex well-structured functional community, inserted in an extracellular polysaccharide 
matrix, and this characteristic is directly related to increased antifungal resistance, as well as 
intrinsic factors of oral cavity (e.g. pH, nutrient availability, gas composition, salivary film and 
possible inflammatory exudate) that may influence the development of these biofilms. Biofilm 
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resistance to conventional antifungal therapy leads to limited treatment options and recurrent 
infection (Zarco et al. 2012; Wade 2013; Cavalcanti et al. 2016; Bassi & Boriollo 2019). 
Due to increased antifungal resistance, prevention and treatments options and searching 
for new biocomponents from medicinal plants with antifungal potential are very important 
(Fonseca et al. 2014; Barua et al. 2017; Shirley et al. 2017). In this context, recent studies have 
analyzed the dose-dependent action of Anadenanthera colubrina (Vell.) Brenan extract on 
Candida sp. biofilms and C. krusei and C. parapsilosis cell viability (Silva et al. 2019), or the 
dose-dependent action of Guapira graciliflora Mart. on the metabolic activity of C. albicans 
biofilm (Almeida et al. 2018). 
Handroanthus impetiginosus (Mart. ex DC.) Mattos (popularly known as pink ipe or 
pink lapacho) is a tree of family Bignoniaceae, and can be found in the tropical forests of South 
America, particularly in Brazil. It has been described in the literature as having phytotherapeutic 
potential. It is also used pharmacologically in the treatment of different clinical conditions, as 
antiangiogenic, antimicrobial, antinociceptive, antiedematogenic, antioxidant, healing, and 
antineoplastic agents. The product extracted from the bark of this tree has in its phytochemical 
composition the presence of components such as naphthoquinones, furanonaphthoquinones, 
anthraquinones, benzoic acid derivatives, benzaldehyde derivatives, iridoids, coumarins, 
flavonoids, and phenylpropanoid glycosides, with lapachol and β-lapachone described as 
having a relevant effect against strains of Candida albicans and related species (Pereira et al. 
2006; Boriollo et al. 2017; Park et al. 2017). However, the literature has no paper exploring the 
anti-biofilm ability of H. impetiginosus extracts. 
Considering the incidence of Candida-associated denture stomatitis, increased 
resistance to antifungal agents and clinical repercussion of this fact, this study analyzed the anti-
biofilm ability of H. impetiginosus bark extracts using in vitro test models and kinetic analysis 
(Bassi & Boriollo 2019) of C. albicans biofilm development on the surface of specimens 
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produced with a prosthetic reline material (vinyl polysiloxane) under the influence of adsorbed 
films. 
 
Material and methods 
Specimens 
Specimens were produced with a flexible material (vinyl polysiloxane) for dental 
prosthesis relining (Silagum-Comfort Soft Relining®, ref. # 909951, batches 735776 and 
761633, DMG Chemisch-Pharmazeutische, Hamburg, Germany) using varnished stainless steel 
molds (Silagum-Comfort Verniz®, ref. # 909089, batch 748329, DMG Chemisch-
Pharmazeutische, Hamburg, Germany), according to the manufacturer’s instructions, and 
sterilized with hydrogen peroxide plasma (Bassi & Boriollo 2019). 
 
Plant extract 
The fluid extract (maceration and percolation) of H. impetiginosus bark (FEHi) was 
obtained commercially and stored according to the manufacturer’s recommendations (Bio Tae 
Indústria e Comércio de Insumos Farmacêuticos, Cosméticos e Alimentícios Ltda., Tatui, SP, 
Brazil). Aliquots of this extract were submitted to rotary evaporation and lyophilization 
(Boriollo et al. 2014). Dry extract (spray dryer) of H. impetiginosus bark (DEHi) was also 
obtained commercially and stored in a hermetically sealed container at room temperature, 
protected from light and moisture, according to the manufacturer’s recommendations (Florien 
Fitoativos Ltda., Piracicaba, SP, Brail). Lyophilized FEHi and DEHi were prepared in an 
aqueous solvent (YNB – yeast nitrogen base, Invitrogen™, Cat. # Q30007, Thermo Fisher 
Scientific, SP, Brazil) at 2 working concentrations, sterilized by filtration (Millipore 
Corporation, hydrophilic PVDF Durapore® membrane filter, 0.45 m,  47 mm, Cat. # HVLP 
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047 00), and stored in 250 ml glass vials (laboratory bottles, code # BOE 5080365, Boeckel + 
Co (GmbH + Co), Hamburg, Germany) at -70 ºC until use. 
 
Planktonic yeast culture 
Recently grown strains of C. albicans ATCC® 90028 (Sabouraud Dextrose Agar, Cat. 
# CM0041B, Thermo Fisher Scientific, SP, Brazil) were cultivated (Laboratory Bottles, code # 
BOE 5080365, Boeckel + Co (GmbH + Co), Hamburg, Germany) in 100 ml of YEPD (yeast 
extract 1% wt/vol, peptone 2% wt/vol, dextrose 2% wt/vol) at 37 C for 24 hours at 150 rpm 
(orbital shaking incubator TE-4200, Tecnal Equipamentos para Laboratório Ltda., Piracicaba, 
SP, Brazil). Cultures were transferred to 50 ml falcon tubes (Corning Inc., Corning, NY, USA), 
centrifuged at 2,500  g (Centrifuge 5417R, Eppendorf do Brasil Ltda., São Paulo, Brazil) for 
5 minutes at -4 C and washed three times in 20 ml sterile PBS solution (100 mM NaCl, 
100 mM NaH2PO4, pH 7.2), applying the same centrifugal force to each wash cycle. For biofilm 
assays, yeast cells were adjusted to a concentration of 1  107 CFU/ml of PBS solution using a 
spectrophotometer (Thermo Scientific Multiskan GO UV/Vis, Microplate and Cuvette 
Spectrophotometer, ref. # 51119200, Thermo Fisher Scientific Inc., Waltham, MA, USA) with 
a wavelength of 600 nm (T = 10%  A 600 nm = 2 – log10 %T  A 600 nm = 1.0) (Chandra et al. 
2001; Li 2003; Mateus et al. 2004). 
 
Preconditioning systems 
Preconditioning systems potentially capable of generating adsorbed films on bodies 
were included (Bassi & Boriollo 2019): planktonic yeast cell wash solution (PBS), artificial 
saliva (AS), fetal bovine serum (FBS), and artificial saliva plus 1:1 fetal bovine serum 
(AS+FBS). 
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Artificial saliva (mucin, 35 g/L; xylitol, 20 g/L; potassium chloride, 1.2 g/L; sodium 
chloride, 0.85 g/L; magnesium chloride hexahydrate, 0.05 g/L; calcium chloride hexahydrate, 
0.2 g/L and dipotassium phosphate, 0.35 g/L) (Roberts et al. 2013) was sterilized by filtration 
(KASVI® model K15-1150) and stored at -20 ºC until use. Fetal bovine serum was obtained 
commercially (fetal bovine serum, qualified, E.U.-approved, South America origin, Gibco™, 
Cat. # 10270106, Thermo Fisher Scientific, SP, Brazil), inactivated at 56 °C for 30 minutes and 
stored at -20 C until use. 
Prior to biofilm assays, specimen groups remained submerged (Laboratory bottles, Code 
# BOE 5080365, Boeckel + Co (GmbH + Co), Hamburg, Germany) in their respective 
preconditioning systems at 37 °C overnight under mild agitation (orbital shaking incubator TE-
4200, TE-4200, Tecnal Equipamentos para Laboratório Ltda., Piracicaba, SP, Brazil) 
(Cavalcanti et al. 2015; Bassi & Boriollo 2019). Then these specimens were aseptically 
transferred to sterile microdilution plate wells (48-well cell culture microplates, flat-bottom, 
Corning Inc., Corning, NY, USA). 
 
Development of control biofilms 
For the development of control biofilms, 500 μl aliquots of C. albicans cell suspension 
(1107 CFU/ml of PBS solution) were transferred to the microdilution plate wells (48-well cell 
culture microplates, flat-bottom, Corning Inc., Corning, NY, USA) containing specimens, then 
they were statically incubated at 37 °C for 1½ hours (adhesion phase). Soon after that, the wells 
containing the specimens were aspirated and carefully washed with sterile PBS solution (2 
500 l) to remove non-adherent (planktonic) yeast cells. Then, the specimens were transferred 
to new microdilution plates containing 500 l YNB broth (yeast nitrogen base, Invitrogen™, 
Cat. # Q30007, Thermo Fisher Scientific, SP, Brazil) supplemented with glucose (100 mM), 
and incubated at 37 C at 75 rpm agitation (Thermo Shaker Dry Block, mod: NI1364 – Nova 
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Instruments, SP, Brazil), for three biofilm development times: 8 hours (initial phase), 24 hours 
(intermediate phase) and 48 hours (maturation phase) (Chandra et al. 2008; da Silva et al. 2010; 
Bassi & Boriollo 2019). Microdilution plates containing YNB broth and specimens from 
different preconditioning groups and biofilm development times, but without aliquots of yeast 
cells, were used as sterility controls 1. All assays were systematically conducted in triplicate. 
 
Anti-biofilm sensitivity test 
Determination of biofilm sessile minimum inhibitory concentration (SMIC), regarding 
Candida albicans biofilm development kinetics on specimens, was conducted by broth 
microdilution, partially based on the procedure issued by the Clinical and Laboratory Standards 
Institute (CLSI 2008), using previously prepared HEHi and DEHi solutions. The tests were 
conducted on microdilution plates (48-well cell culture microplates, flat-bottom, Corning Inc., 
Corning, NY, USA) containing 500 µl of YNB with FEHi or DEHi per well at final 
concentrations from 3.125 to 200 mg/ml). 
C. albicans adherent cells and/or biofilms on pre-conditioned specimens (PBS, AS, FBS 
and AS+FBS) and from different development phases (1½, 8, 24 and 48 hours) were carefully 
washed with sterile PBS solution (2 500 l). Then their respective specimens were transferred 
to the wells of microdilution plates containing YNB with FEHi or DEHi, and then incubated at 
37 °C for 24 hours and constant agitation at 75 rpm. 
Microdilution plates containing YNB broth with FEHi or DEHi, but without the 
specimens and their respective adherent cells or biofilms developed in different phases, were 
used as sterility controls 2. All assays were systematically conducted in triplicate. 
 
Bioactivity test 
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C. albicans biofilm development kinetics on specimen surface was monitored through 
reduction assay of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT), a semi-quantitative measurement of biofilm formation (Chandra 
et al. 2008; da Silva et al. 2010; Bassi & Boriollo 2019). 
Aliquots of 10 ml were produced from saturated solutions (500 mg/L in PBS solution) 
of XTT (XTT sodium salt, SIGMA Cat. # X4626, Sigma Chemical Co.), then sterilized by 
filtration (Millipore Corporation, hydrophilic Durapore® PVDF, 0.22 μm,  47 mm, Cat. # 
GVWP 047 00) and stored at -70 C until use. Prior to the assays, a recently prepared 
menadione solution (10 mM in acetone; Menadione crystalline, SIGMA Cat.# M5625, Sigma 
Chemical Co.) was added to the aliquots of thawed XTT saturated solution (final menadione 
concentration of 1 M). This XTT-menadione solution was added to the microdilution plate 
wells (48-well cell culture microplates, flat-bottom, Corning Inc., Corning, NY, USA) in 
aliquots of 200 l. 
Once the development phases of the control or FEHi- or DEHi-treated biofilms were 
completed, the respective specimens were carefully washed twice with PBS solution, 
transferred to the microdilution plates containing the XTT-menadione solution, and statically 
incubated at 37 °C for 5 hours. Then, 100 l aliquots of each well were gently transferred to 
microdilution plates (96-well cell culture microplates, Corning Inc., Corning, NY, USA) and 
the soluble formazan product was quantified by spectrophotometry at 492 nm (Thermo 
Scientific NanoDrop® 2000c Spectrophotometer, Wilmington, DE, USA). 
 
Confocal Laser Scanning Microscope (CLSM) 
The growth kinetics of biofilms against the specimens was analyzed by Confocal Laser 
Scanning Microscope (LEICA TCS SP5 Microscope, Leica Microsystems, Wetzlar, Germany). 
The initial conditions of this assay were performed as previously described (see 2.5 and 2.6). 
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Preconditioning favorable to higher cellular metabolic activity (data obtained from 2.7), all 
times of the biofilm growth kinetics (1 ½, 8, 24, and 48h), and plant extract treatments (FEHi 
and DEHi: minimum concentration incapable of fully inhibiting metabolic activity) were used 
as inclusion criteria for the assay (Bassi & Boriollo 2019). 
After these initial assays, specimens were washed 3 with 500 µl of PBS solution and 
fixed (lower portions) with instant adhesive (Loctite - Super Bonder®, Henkel Ltda., São Paulo) 
in coverslips (18mm  18mm – KASVI/Olen®, model k5-1818). Excess moisture from 
specimens was carefully removed by the contact between their lower portions and sterile filter 
aper (Whatman n3). Adhered cells and/or biofilms on the upper surfaces of specimens were 
carefully submerged in fluorescent dye solution (LIVE/DEAD™ BacLight™ Bacterial 
Viability Kit, Invitrogen™, Cat. # L7007, Eugene, OR, USA) for 15 minutes and in PBS 
solution for 10 seconds. With this method we can monitor cell viability regarding the cell 
membrane integrity. Therefore, cells with compromised membrane (non-viable) are visualized 
in reddish stain, whereas cells with intact membrane (viable) are visualized in greenish stain 
and, depending on the intensity of both dyes in overlapping images, non-viable cells are 
visualized in yellowish stain (Bassi & Boriollo 2019). 
A chamber (chamber glass bottom dishes, BioImager®, Cat. #100350, Vaughan, 
Ontario, Canada), with a polypropylene ring (13mm  3mm) adapted and fixed to the center, 
was used to support specimens fixed in the coverslip. This adaptation allowed each fixed 
specimen to remain submerged in PBS solution and without contact with the surface of the 
chamber, thus avoiding structural damage in the biofilm throughout analyses by inverted 
confocal laser scanning microscope (Bassi & Boriollo 2019). 
The cell viability (percentage of green pixels: viable cells; percentage of red/yellow 
pixels: non-viable cells), relative biomass of biofilm (PX    m   3m3 m nn   , 
where PX and m are units of measurements in pixels and micrometers, respectively; 1 m = 
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1.2933 pixels or 1m3 = 1.089515 pixels) and thickness of the biofilm (µm) were evaluated by 
images captured in intervals of 1 µm and using the Leica LAS AF Lite software (LEICA, 
Wetzlar, Germany). The 3D reconstruction of the biofilm was made using the Fiji software, 
version 2.0.0-RC-67/1.52 C (National Institutes of Health de Wayne Rasband, Bethesda, United 
States of America) (Bassi & Boriollo 2019). 
 
Scanning electron microscopy (MEV) 
C. albicans biofilm development kinetics on specimen surface analyzed by scanning 
electron microscopy (SEM; JEOL-JSM-5600LV; 15 kV, JEOL Ltd., Akishima, Japan). The 
initial procedure of this assay was performed as previously described (2.5 and 2.6). All 
preconditions (PBS, AS, FBS and AS+FBS), times of biofilm formation kinetics (1½, 8, 24 and 
48h) and treatments with FEHi or DEHi at minimum concentration unable to fully inhibit the 
metabolic activity were used as inclusion criteria for the tests (Bassi & Boriollo 2019). 
After the initial tests, the specimens were washed 3 with 500 µl of PBS solution and 
fixed (lower portions) with instant adhesive (Loctite - Super Bonder®, Henkel Ltda., São Paulo) 
to slides (26 mm  76 mm – KASVI/Olen®, model k5-7105) for biofilm fixation and 
dehydration procedure. Fixation was performed by immersing the slides in 2.0% glutaraldehyde 
solution (glutaraldehyde solution, grade I, 25%, SIGMA Cat. # G5882, Sigma Chemical Co.) 
for 30 minutes at room temperature, followed by 10-minute baths at increasing concentrations 
of ethanol (50%, 70%, 90%, 95% and 100%). After drying, the slides were submitted to gold 
plating for 120s (BAL-TEC − SCD 050 − Sputter Coater, Balzers, Liechtenstein) and stored in 
a desiccator for subsequent analysis. A morphological analysis of biofilm structures was 
performed by scanning electron microscopy (JEOL-JSM-5600LV; 15 kV, JEOL Ltd., 
Akishima, Japan) at a magnitude of 1,500. 
 
61 
 
 
Statistical analysis 
Semiquantitative data obtained from the XTT reduction assays, from the growth kinetics 
of C. albicans biofilms, were submitted to one-way analysis of variance (ANOVA), according 
to a factor scheme of 6  4  4 (time  surface  treatment) and the comparison of means by 
the Tukey test ( = 0.05), using the SAS® software, version 9.2 (Bassi & Boriollo 2019). 
The biofilm sessile minimum inhibitory concentration capable of reducing 50% 
(SMIC50) and 80% (SMIC80) of the metabolic bioactivity was calculated by regression analysis, 
using the mean of absorbance values (492 nm) of the data of all preconditionings (PBS, AS, 
FBS, and AS+FBS) (Bassi & Boriollo 2019). 
Biological parameters (non-viable cells) and those of magnitude (relative biomass and 
thickness) of the growth kinetics of C. albicans biofilms, under the influence of the adsorb film 
(FBS) and exposure to antifungal agents, were also subjected to one-way analysis of variance 
(ANOVA), according to a factor scheme of 4  4 (time  treatment) and comparison of means 
by Tukey test ( = 0.05), using the SAS® software version 9.2 (Bassi & Boriollo 2019). 
 
Results 
Bioactivity of biofilm formation kinetics 
The effects of FEHi and DEHi treatments on the development kinetics of C. albicans 
biofilms on preconditioned specimen surfaces showed statistical significance (p0.05) between 
the mean values of absorbance (XTT reduction assay) at tested concentrations, and variable 
SMICs50-80 values for each extract. 
FEHi treatment resulted in partial dose-dependent inhibition of metabolic activity of C. 
albicans biofilm development kinetics at all tested concentrations (p0.05), when compared to 
sterility control 1 (YNB). However, full inhibition of this metabolic activity can be considered 
from 100 mg/ml, when compared to sterility control 2 (YNB + FEHi) (Table 1 and Figure 
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1A). Preconditioning with FBS allowed significantly higher cell bioactivity (p0.05) for 
biofilm development kinetics, while the effect of the other films (AS, AS+FBS and PBS) was 
considered statistically indifferent (p0.05) (Table 1 and Figure 1B). C. albicans biofilms 
obtained after 48 hours (maturation phase) treated with FEHi showed significantly higher 
metabolic activities (p0.05), followed by 24-hour biofilms (intermediate phase) and 8-hour 
biofilms (initial phase) or 1½ hours (cell adhesion) (Table 1 and Fig 1C). The biofilm sessile 
minimum inhibitory concentration of FEHi was (Figure 3): 
 Adhesion phase (1½h): SMIC80 corresponded to 3.125 mg/ml; 
 Initial phase (8h): SMIC80 corresponded to 3.125 mg/ml; 
 Intermediate phase (24h): SMIC50 and SMIC80 corresponded to 3.125 and 6.25 mg/ml, 
respectively; 
 Maturation phase (48h): SMIC50 and SMIC80 corresponded to 6.25 mg/ml and 200 
mg/ml, respectively. 
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Table 1. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida albicans 
biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb films and 
fluid extract of Handroanthus impetiginosus (FEHi).  
 
Treatment Time Direct test systemB Preconditioning test systems 
 (hour)   ASB BFSA AS and BFSB 
  Mean SD Mean SD Mean SD Mean SD 
Growth control 1 ½ 0.3341 0.0156 0.3250 0.0103 0.3719 0.0109 0.3461 0.0190 
(YNB and yeast)A 8 0.3075 0.0014 0.3075 0.0014 0.3308 0.0100 0.3274 0.0058 
 24 0.3073 0.0032 0.3447 0.0177 0.3888 0.0091 0.3508 0.0033 
  48 0.3204 0.0225 0.3518 0.0330 0.3637 0.0248 0.3498 0.0182 
Sterility control 1 1 ½ 0.0466 0.0012 0.0473 0.0013 0.0449 0.0029 0.0485 0.0019 
(YNB)E 8 0.0456 0.0029 0.0501 0.0053 0.0494 0.0018 0.0522 0.0060 
  24 0.0484 0.0015 0.0482 0.0013 0.0485 0.0010 0.0474 0.0001 
  48 0.0479 0.0009 0.0479 0.0002 0.0476 0.0001 0.0477 0.0002 
Sterility control 2 1 ½ 0.0751 0.0156 0.0788 0.0171 0.0723 0.0183 0.0761 0.0147 
(YNB and 8 0.0751 0.0156 0.0788 0.0171 0.0723 0.0183 0.0761 0.0147 
FEHi 24 0.0751 0.0156 0.0788 0.0171 0.0723 0.0183 0.0761 0.0147 
200 mg/ml)DE 48 0.0751 0.0156 0.0788 0.0171 0.0723 0.0183 0.0761 0.0147 
FEHi 1 ½C                 
3.125 mg/mlB   0.0619 0.0025 0.0649 0.0027 0.0932 0.0030 0.0914 0.0003 
6.25 mg/mlC   0.0633 0.0021 0.0594 0.0025 0.0739 0.0022 0.0736 0.0141 
12.5 mg/mlC   0.0637 0.0064 0.0588 0.0056 0.0913 0.0005 0.0723 0.0091 
25 mg/mlC   0.0727 0.0111 0.0695 0.0100 0.0910 0.0002 0.0903 0.0093 
50 mg/mlC   0.0766 0.0031 0.0621 0.0077 0.0838 0.0052 0.0797 0.0010 
100 mg/mlCD   0.0771 0.0011 0.0665 0.0044 0.0800 0.0010 0.0619 0.0028 
200 mg/mlCD   0.0838 0.0004 0.0857 0.0017 0.0811 0.0001 0.0866 0.0005 
FEHi 8C                 
3.125 mg/mlB   0.0860 0.0015 0.0851 0.0016 0.1059 0.0058 0.0979 0.0008 
6.25 mg/mlC   0.0885 0.0018 0.0872 0.0028 0.1087 0.0010 0.0866 0.0008 
12.5 mg/mlC   0.0866 0.0008 0.0868 0.0004 0.0866 0.0015 0.0848 0.0035 
25 mg/mlC   0.0871 0.0032 0.0874 0.0034 0.0833 0.0034 0.0776 0.0018 
50 mg/mlC   0.0817 0.0014 0.0875 0.0051 0.0819 0.0003 0.0767 0.0048 
100 mg/mlCD   0.0837 0.0037 0.0831 0.0014 0.0812 0.0000 0.0815 0.0002 
200 mg/mlCD   0.0780 0.0062 0.0888 0.0005 0.0847 0.0027 0.0816 0.0001 
FEHi 24B                 
3.125 mg/mlB   0.1133 0.0045 0.1090 0.0018 0.1857 0.0104 0.1287 0.0032 
6.25 mg/mlC   0.1096 0.0017 0.0997 0.0000 0.1221 0.0023 0.1112 0.0006 
12.5 mg/mlC   0.1091 0.0022 0.0979 0.0007 0.1206 0.0001 0.1106 0.0000 
25 mg/mlC   0.1062 0.0050 0.0976 0.0007 0.1072 0.0003 0.1064 0.0007 
50 mg/mlC   0.1114 0.0050 0.0961 0.0028 0.1066 0.0005 0.1001 0.0034 
100 mg/mlCD   0.1022 0.0037 0.0895 0.0006 0.0924 0.0042 0.0912 0.0002 
200 mg/mlCD   0.0915 0.0067 0.0835 0.0036 0.0881 0.0010 0.0815 0.0002 
FEHi 48A                 
3.125 mg/mlB   0.2134 0.0043 0.1798 0.0017 0.2476 0.0138 0.1751 0.0042 
6.25 mg/mlC   0.1512 0.0005 0.1345 0.0056 0.1711 0.0007 0.1506 0.0004 
12.5 mg/mlC   0.1411 0.0005 0.1243 0.0057 0.1611 0.0004 0.1215 0.0109 
25 mg/mlC   0.1315 0.0019 0.1203 0.0120 0.1608 0.0001 0.1119 0.0017 
50 mg/mlC   0.1230 0.0036 0.1125 0.0106 0.1511 0.0005 0.1097 0.0003 
100 mg/mlCD   0.1064 0.0050 0.1052 0.0081 0.1421 0.0005 0.1039 0.0036 
200 mg/mlCD   0.0822 0.0012 0.0992 0.0087 0.1321 0.0063 0.0924 0.0054 
Means with the same letter (A, B, C, D or E) are not significantly different (p  0.05). Shown are data from the controls 
(growth and sterility 1 and 2) and different concentrations of FEHi. SD, AS and BFS correspond to standard derivation, 
artificial saliva and bovine fetal serum, respectively. 
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Figure 1. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb 
films and fluid extract of Handroanthus impetiginosus (FEHi): treatment (A), surface (B), and time (C). AS 
and FBS correspond to artificial saliva and bovine fetal serum, respectively. Direct test (sterile PBS solution). 
Means with the same letter (A, B, C, D or E) are not significantly different (p  0.05). 
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Figure 2. Biofilm sessile minimum Inhibitory concentration (SMIC) profiles of fluid extract 
and dry extract of Handroanthus impetiginosus (FEHi and DEHi) obtained from the growth 
kinetics of Candida albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) 
and under the influence of adsorb films. 
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DEHi treatment resulted in partial dose-dependent inhibition of metabolic activity of C. 
albicans biofilm development kinetics at all tested concentrations (p0.05), regardless of 
comparison with sterility controls 1 and 2 (Table 2 and Figure 2A). Preconditioning with FBS 
also favored significantly higher cell bioactivity (p0.05) for biofilm development kinetics, 
followed by preconditioning with AS+FBS or PBS, and AS only (p  0.05) (Table 2 and Figure 
2B). Cell adhesion (1½ hours) to DEHi-treated specimens showed significantly higher 
metabolic activities (p0.05), followed by 48-hour biofilms (maturation phase) and 24-hour 
biofilms (intermediate phase) or 8-hour biofilms (initial phase) (Table 2 and Fig 3C). The 
biofilm sessile minimum inhibitory concentration of DEHi was (Figure 3): 
 Adhesion phase (1½h): SMIC50  (SMIC50 probably corresponded to 200 mg/ml); 
 Initial phase (8h): SMIC50 corresponded to 50 mg/ml; 
 Intermediate phase (24h): SMIC50 corresponded to 25 mg/ml; 
 Maturation phase (48h): SMIC50 corresponded to 100 mg/ml; 
SMIC80 was not observed at tested concentrations of DEHi (3.125–200 mg/ml). 
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Table 2. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida albicans 
biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb films and 
dry extract of Handroanthus impetiginosus (DEHi).  
 
Treatment Time Direct test systemB Preconditioning test systems 
 (hour)   ASC BFSA AS and BFSB 
  Mean SD Mean SD Mean SD Mean SD 
Growth control 1 ½ 0.3341 0.0156 0.3250 0.0103 0.3719 0.0109 0.3461 0.0190 
(YNB and yeast)A 8 0.3075 0.0014 0.3075 0.0014 0.3308 0.0100 0.3274 0.0058 
 24 0.3073 0.0032 0.3447 0.0177 0.3888 0.0091 0.3508 0.0033 
  48 0.3204 0.0225 0.3518 0.0330 0.3637 0.0248 0.3498 0.0182 
Sterility control 1 1 ½ 0.0466 0.0012 0.0473 0.0013 0.0449 0.0029 0.0485 0.0019 
(YNB)I 8 0.0456 0.0029 0.0501 0.0053 0.0494 0.0018 0.0522 0.0060 
  24 0.0484 0.0015 0.0482 0.0013 0.0485 0.0010 0.0474 0.0001 
  48 0.0479 0.0009 0.0479 0.0002 0.0476 0.0001 0.0477 0.0002 
Sterility control 2 1 ½ 0.0543 0.0020 0.0581 0.0017 0.0560 0.0010 0.0566 0.0004 
(YNB and 8 0.0543 0.0020 0.0581 0.0017 0.0560 0.0010 0.0566 0.0004 
DEHi 24 0.0543 0.0020 0.0581 0.0017 0.0560 0.0010 0.0566 0.0004 
200 mg/ml)I 48 0.0543 0.0020 0.0581 0.0017 0.0560 0.0010 0.0566 0.0004 
DEHi 1 ½A                 
3.125 mg/mlB   0.3652 0.0102 0.2238 0.0048 0.3795 0.0014 0.2582 0.0047 
6.25 mg/mlC   0.3524 0.0133 0.2064 0.0090 0.3793 0.0022 0.2420 0.0115 
12.5 mg/mlD   0.3509 0.0091 0.1960 0.0054 0.3765 0.0002 0.2438 0.0083 
25 mg/mlE   0.3523 0.0254 0.1811 0.0132 0.3620 0.0150 0.2313 0.0139 
50 mg/mlF   0.3075 0.0021 0.1595 0.0013 0.3406 0.0002 0.2194 0.0120 
100 mg/mlG   0.3056 0.0026 0.1276 0.0077 0.3406 0.0001 0.2058 0.0032 
200 mg/mlH   0.2485 0.0251 0.1133 0.0034 0.3406 0.0002 0.1546 0.0069 
DEHi 8C                 
3.125 mg/mlB   0.2532 0.0059 0.2049 0.0099 0.3810 0.0111 0.3043 0.0027 
6.25 mg/mlC   0.2048 0.0040 0.1825 0.0010 0.3631 0.0034 0.2435 0.0075 
12.5 mg/mlD   0.1643 0.0018 0.1542 0.0016 0.3533 0.0075 0.2302 0.0048 
25 mg/mlE   0.1526 0.0002 0.1461 0.0046 0.3386 0.0059 0.1954 0.0015 
50 mg/mlF   0.1466 0.0042 0.1396 0.0067 0.2878 0.0052 0.1952 0.0084 
100 mg/mlG   0.1430 0.0021 0.1275 0.0027 0.2339 0.0019 0.1872 0.0051 
200 mg/mlH   0.1399 0.0022 0.1036 0.0028 0.2105 0.0054 0.1804 0.0038 
DEHi 24C                 
3.125 mg/mlB   0.2558 0.0067 0.2213 0.0002 0.3453 0.0035 0.2770 0.0067 
6.25 mg/mlC   0.2428 0.0011 0.2153 0.0018 0.3170 0.0101 0.2108 0.0047 
12.5 mg/mlD   0.1847 0.0044 0.2137 0.0008 0.3024 0.0033 0.2093 0.0055 
25 mg/mlE   0.1729 0.0020 0.1849 0.0041 0.2458 0.0048 0.1767 0.0049 
50 mg/mlF   0.1709 0.0016 0.1731 0.0129 0.2160 0.0066 0.1486 0.0109 
100 mg/mlG   0.1670 0.0051 0.1458 0.0055 0.1630 0.0062 0.1317 0.0009 
200 mg/mlH   0.1491 0.0018 0.1367 0.0090 0.1433 0.0045 0.1254 0.0010 
DEHi 48B                 
3.125 mg/mlB   0.3166 0.0006 0.3158 0.0008 0.3295 0.0003 0.3193 0.0001 
6.25 mg/mlC   0.2679 0.0108 0.3048 0.0011 0.2848 0.0020 0.2878 0.0024 
12.5 mg/mlD   0.2352 0.0044 0.2231 0.0090 0.2772 0.0020 0.2643 0.0010 
25 mg/mlE   0.2140 0.0022 0.2185 0.0049 0.2217 0.0000 0.2575 0.0031 
50 mg/mlF   0.1923 0.0029 0.2095 0.0021 0.2164 0.0005 0.2120 0.0058 
100 mg/mlG   0.1752 0.0212 0.2041 0.0019 0.1854 0.0015 0.1877 0.0062 
200 mg/mlH   0.1495 0.0119 0.1311 0.0049 0.1634 0.0063 0.1555 0.0042 
Means with the same letter (A, B, C, D, E, F, G, H or I) are not significantly different (p  0.05). Shown are data from the 
controls (growth and sterility 1 and 2) and different concentrations of DEHi. SD, AS and BFS correspond to standard 
derivation, artificial saliva and bovine fetal serum, respectively. 
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Figure 3. Semiquantitative profile (XTT reduction assay) obtained from the growth kinetics of Candida 
albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb 
films and dry extract of Handroanthus impetiginosus (DEHi): treatment (A), surface (B), and time (C). AS 
and FBS correspond to artificial saliva and bovine fetal serum, respectively. Direct test (sterile PBS solution). 
Means with the same letter (A, B, C, D, E, F, G, H, or I) are not significantly different (p  0.05). 
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Figure 4. Biofilm sessile minimum Inhibitory concentration (SMIC) profiles of fluid extract 
and dry extract of Handroanthus impetiginosus (FEHi and DEHi) obtained from the growth 
kinetics of Candida albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) 
and under the influence of adsorb films. 
 
 
 
 
 
Three-dimensional structure of biofilm 
 Confocal laser scanning microscopy (CLSM) analyses were performed to determine 
relative non-viable cells and relative biomass and thickness parameters in C. albicans biofilm 
development kinetics (1½, 8, 24 and 48h) on specimens (vinyl polysiloxane prosthetic reline 
material) exposed to FEHi and DEHi. For these assays, preconditioning with FBS favored 
higher cellular metabolic activity, while FEHi and DEHi concentration considered minimally 
desirable and unable to fully inhibit cellular metabolic activity was 12.5 mg/ml (SMIC50  
[FEHi]  SMIC100; SMIC1  [DEHi]  SMIC50), as previously determined in XTT reduction 
assay. 
 Under the conditions established for this assay, treatments with FEHi or DEHi (identical 
concentrations) for C. albicans biofilm development kinetics on specimen surface showed no 
statistical differences (p0.05), either for the biological parameter (percentage non-viable cells) 
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or relative biomass and thickness parameters. No statistically significant variation was observed 
between the development phases of C. albicans biofilm on specimens and when exposed to the 
extracts (p0.05), considering the percentage of non-viable cells (biological parameters) and 
relative biomass of biofilm (magnitude parameters). However, significant variations (p0.05) 
were observed between these phases when considering the thickness (magnitude parameters), 
with or without exposure to FEHi or DEHi [i.e., thickness (µm) of adherent cells and biofilms 
was time-dependent (p0.05)] (Table 3; Figures 4 and 5). 
 
Table 3. Biological parameters (non-viable cells) and magnitude parameters (relative biomass and thickness) 
in the growth kinetics of C. albicans biofilms against specimens (vinyl polysiloxane prosthesis rebase) and 
under the influence of adsorb film (FBS) and fluid extract and dry extract of Handroanthus impetiginosus 
(12,5 mg/ml: FEHi and DEHi), obtained from Confocal Laser Scanning Microscope (CLSM) analysis. Data 
generated by Leica LAS AF Lite software (LEICA, Wetzlar, Germany).  
 
 
Treatment Non-viable cells (%)* 
 1½hA 8hA 24hA 48hA 
AbsentA 0.001 9.601 14.136 47.937 
FEHiA 48.881 43.011 46.569 33.106 
DEHiA 53.583 39.314 47.557 33.893 
Treatment Relative biomass of biofilm (µm3) 
 1½hA 8hA 24hA 48hA 
AbsentA 154.800 178.914 181.303 220.361 
FEHiA 213.415 212.116 234.895 210.291 
DEHiA 198.805 230.442 216.546 201.783 
Treatment Thickness of the biofilm (µm) 
 1½hB 8hB 24hAB 48hA 
AbsentA 33 42 60 123 
FEHiA 36 38 60 73 
DEHiA 29 37 65 82 
*Cells with a compromised membrane that are deemed dead or dying. 
Values with the same letter (A or B) are not significantly different (p  
0.05). 
 
 
 
Figure 5. Biological parameters (non-viable cells) and magnitude parameters (relative biomass 
and thickness) in the growth kinetics of C. albicans biofilms against specimens (vinyl 
polysiloxane prosthesis rebase) and under the influence of adsorb film (FBS) and fluid extract 
and dry extract of Handroanthus impetiginosus (FEHi and DEHi: 12,5 mg/ml), obtained from 
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Confocal Laser Scanning Microscope (CLSM) analyses. Values with the same letter (A and B) 
are not significantly different (p  0.05). 
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Figure 6. CLSM images in different growth periods of Candida albicans biofilms against 
specimens (vinyl polysiloxane prosthesis rebase) and under the influence of adsorb film (FBS) 
and fluid extract and dry extract of Handroanthus impetiginosus (FEHi and DEHi: 12,5 mg/ml). 
3D images generated by the Fiji v.2.0.0-rc- 67/1.52c software (National Institutes of Health de 
Wayne Rasband, Bethesda, United States of America). 
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Green: 99.999%     Green: 51.119%       Green: 46.417% 
Red: 0.001%     Red: 48.881%       Red: 53.583% 
T: 33m      T: 36m        T: 29m 
RB: 154.800µm3     RB: 213.415µm3       RB: 198.805µm3 
Control                                                                    FEHi                                                                       DEHi 
 
 
 
 
 
 
 
Green: 90.399%     Green: 56.989%       Green: 60.686% 
Red: 9.601%     Red: 43.011%       Red: 39.314% 
T: 42m      T: 38m        T: 37m 
RB: 178.914µm3     RB: 212.116µm3       RB: 230.442µm3 
Control                                                                    FEHi                                                                       DEHi 
 
 
 
 
 
 
 
Green: 85.864%     Green: 53.431%       Green: 52.443% 
Red: 14.136%     Red: 46.569%       Red: 47.557% 
T: 60m      T: 60m        T: 65m 
RB: 181.303µm3     RB: 234.895µm3       RB: 216.546µm3 
Control                                                                    FEHi                                                                       DEHi 
 
 
 
 
 
 
 
Green: 52.063%     Green: 66.894%       Green: 66.107% 
Red: 47.937%     Red: 33.106%       Red: 33.893% 
T: 123m      T: 73m        T: 82m 
RB: 220.361µm3     RB: 210.291µm3       RB: 201.783µm3 
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Scanning Electron Microscope (SEM) 
 C. albicans biofilm development kinetics (1½, 8, 24 and 48h) on the surface of 
specimens exposed or not to FEHi or DEHi was investigated by scanning electron microscopy 
(SEM). Dimorphism characteristics of C. albicans species were observed throughout the 
development phases of control biofilms: yeast and hypha cells, including sprouting or budding 
and evident scars. Cell and/or biofilm density of C. albicans (hypha and yeast) gradually 
increased throughout the development phases (Figure 6). The exposure of C. albicans biofilm 
development kinetics to FEHi and DEHi showed the following characteristics: 
 Adhesion phase (1½h): FEHi treatment resulted in reduced cell volume (yeast), a 
significant decrease in the number of hypha and reduced cell adhesion density versus 
control; DEHi treatment resulted in reduced volume of dimorphic structures (yeast and 
hypha), an increase in the proportion of coenocytic hypha when compared to yeast, and 
a small increase in cell density versus control. 
 Initial phase (8h): FEHi treatment resulted in reduced volume of dimorphic structures 
(yeast and hypha), an increase in the proportion of coenocytic hypha when compared to 
yeast, and an increase in cell density versus control; DEHi treatment resulted in reduced 
volume of dimorphic structures (yeast and hypha), an increase in the proportion of yeast 
when compared to coenocytic hypha, and maintenance of cell density versus control. 
 Intermediate phase (24h): FEHi treatment resulted in reduced volume of dimorphic 
structures (yeast and hypha), a significant increase in the proportion of yeast when 
compared to coenocytic hypha, and maintenance of cell density versus control; DEHi 
treatment resulted in reduced volume of dimorphic structures (yeast and hypha), 
equivalent proportions of coenocytic hypha and yeast, and maintenance of cell density 
versus control. 
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 Maturation phase (48h): FEHi treatment resulted in reduced volume of dimorphic 
structures (yeast and hypha), a significant increase in the proportion of yeast when 
compared to coenocytic hypha, and reduced cell density versus control; DEHi treatment 
resulted in reduced volume of dimorphic structures (yeast and hypha), a significant 
increase in the proportion of yeast when compared to coenocytic hypha, and reduced 
cell density versus control. 
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Figure 6. Scanning Electron Microscope (SEM) images displaying the kinetics of C. albicans biofilms development at different phases and 
exposed to the FEHi and DEHi (12.5 mg/ml). Magnification of Images generated by JEOL-JSM-5600LV (1,500, 15 kV, JEOL Ltd., 
Akishima, Japan). 
 
   
   
Control (1 ½h)                                                                                   FEHi (1 ½h)                                                                                   DEHi (1 ½h) 
    Control (8h)                                                                                       FEHi (8h)                                                                                       DEHi (8h) 
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Figure 6. Scanning Electron Microscope (SEM) images displaying the kinetics of C. albicans biofilm development at different phases and 
exposed to the FEHi and DEHi (12.5 mg/ml). Images generated by JEOL-JSM-5600LV (1,500, 15 kV, JEOL Ltd., Akishima, Japan). 
 
   
   
    Control (24h)                                                                                     FEHi (24h)                                                                                     DEHi (24h) 
    Control (48h)                                                                                     FEHi (48h)                                                                                     DEHi (48h) 
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Potential correlation: XTT assay, CLSM, and SEM  
The profiles of metabolic activities, biological and magnitude parameters and 
ultrastructural morphologies were listed in order to allow a possible association of FEHi and 
DEHi effects and between the extracts throughout the development of C. albicans biofilms. 
(Table 4). In general, the main variations of the effects between FEHi and DEHi occurred in 
the adhesion and initial phases, while these effects were similar when comparing FEHi and 
DEHi in the intermediate and maturation phases of the biofilms. 
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Table 4. Comparison of FEHi and DEHi effects on structural morphology, metabolic activity, and biological and magnitude parameters of 
C. albicans biofilm development. 
 
Biofilm 
development 
kinetics  
Ultrastructural morphology (SEM) 
  
 Metabolic bioactivity (XTT assay)  Biological and magnitude parameters 
(CLSM) 
FEHi DEHi  FEHi DEHi  FEHi DEHi 
Adhesion phase 
(1½h) 
 Reduction of cell 
volume (yeast). 
 Significant decrease in 
the number of hypha. 
 Reduced cell adhesion 
density. 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Increased proportion of 
coenocytic hyphae 
when compared to 
yeast. 
 Small increase in cell 
density versus control. 
  Reduces cellular metabolic 
activity. 
 Dose-dependent, surface-
dependent and phase-
dependent anti-biofilm action. 
 On average, significant 
inhibition starting at the 
concentration of 100 mg/ml, 
especially in cell adhesion 
and initial phases (1½h and 
8h). 
 SMIC80 of 3.125 mg/ml. 
 Partially reduces cellular 
metabolic activity. 
 Dose-dependent, surface-
dependent and phase-
dependent anti-biofilm action. 
 Partial inhibition at all tested 
concentrations (3.125–
200 mg/ml), especially in 
initial and intermediate phases 
(8h and 24h). 
 SMIC80 not observed. 
  No changes in biological and magnitude 
parameters throughout the biofilm 
phases. 
 Thickness is time-dependent (smaller in 
height). 
Initial phase (8h)  Reduced volume of 
dimorphic structures 
(yeast and hypha).  
 Increased proportion of 
coenocytic hyphae 
when compared to 
yeast.  
 Increase in cell density 
versus control. 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Increased proportion of 
yeast when compared 
to coenocytic hyphae. 
 Maintenance of cell 
density versus control. 
  Reduces cellular metabolic 
activity. 
 C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 On average, significant 
inhibition starting at the 
concentration of 100 mg/ml, 
especially in cell adhesion 
and initial phases (1½h and 
8h). 
 SMIC80 of 3.125 mg/ml. 
 Partially reduces cellular 
metabolic activity; 
C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 Partial inhibition at all tested 
concentrations (3.125–
200 mg/ml), especially in 
initial and intermediate phases 
(8h and 24h). 
 SMIC80 not observed.  
  No changes in biological and magnitude 
parameters throughout the biofilm 
phases. 
 Thickness is time-dependent (smaller in 
height). 
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Table 4. Comparison of FEHi and DEHi effects on structural morphology, metabolic activity, and biological and magnitude parameters of 
C. albicans biofilm development. 
 
Biofilm 
development 
kinetics  
Ultrastructural morphology (SEM) 
  
 Metabolic bioactivity (XTT assay)  Biological and magnitude parameters 
(CLSM) 
FEHi DEHi  FEHi DEHi  FEHi DEHi 
Intermediate phase 
(24h) 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Significant increase in 
the proportion of yeast 
when compared to 
coenocytic hyphae. 
 Maintenance of cell 
density versus control. 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Equivalent proportions 
of coenocytic hypha 
and yeast. 
 Maintenance of cell 
density versus control. 
  Reduces cellular metabolic 
activity. 
 C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 On average, significant 
inhibition starting at the 
concentration of 100 mg/ml, 
especially in cell adhesion 
and initial phases (1½h and 
8h). 
 SMIC80 of 6.25 mg/ml. 
 Partially reduces cellular 
metabolic activity; 
C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 Partial inhibition at all tested 
concentrations (3.125–
200 mg/ml), especially in 
initial and intermediate phases 
(8h and 24h). 
 SMIC80 not observed. 
  No changes in biological and magnitude 
parameters throughout the biofilm 
phases. 
 Thickness is time-dependent (smaller in 
height). 
Maturation phase 
(48h) 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Significant increase in 
the proportion of yeast 
when compared to 
coenocytic hyphae. 
 Reduced cell density 
versus control. 
 Reduced volume of 
dimorphic structures 
(yeast and hypha). 
 Significant increase in 
the proportion of yeast 
when compared to 
coenocytic hyphae. 
 Reduced cell density 
versus control. 
  Reduces cellular metabolic 
activity. 
 C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 On average, significant 
inhibition starting at the 
concentration of 100 mg/ml, 
especially in cell adhesion 
and initial phases (1½h and 
8h). 
 SMIC80 of 200 mg/ml. 
 Partially reduces cellular 
metabolic activity. 
 C. albicans anti-biofilm 
action is dose-dependent, 
surface-dependent and phase-
dependent. 
 Partial inhibition at all tested 
concentrations (3.125–
200 mg/ml), especially in 
initial and intermediate phases 
(8h and 24h). 
 SMIC80 not observed. 
  No changes in biological and magnitude 
parameters throughout the biofilm 
phases. 
 Thickness is time-dependent (smaller in 
height). 
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Discussion 
Antifungal and anti-biofilm action of H. impetiginosus bark (FEHi and DEHi) was 
evaluated using in vitro models of the development kinetics (1½h, 8h, 24h and 48h) of 
C. albicans biofilms on the surface of specimens (varnished vinyl polysiloxane – Silagum-
Comfort Verniz®), preconditioned (FBS, AS, FBS+AS and PBS), metabolic activity assay 
(XTT assay), ultramorphological (CLSM and SEM) and statistical analyses. 
FEHi and DEHi showed dose-dependent, surface-dependent and phase-dependent C. 
albicans anti-biofilm action, as both extracts reduced cellular metabolic activities. FEHi 
significantly inhibited cellular metabolic activity starting at the concentration of 100 mg/ml, 
acting throughout the development kinetics and especially in the cell adhesion and initial phases 
(1½h and 8h). SMIC80 of FEHi was 3.125, 6.25 and 200 mg/ml for the adhesion phase (1½h) 
or initial (8h), intermediate (24h) and maturation (48h) phases of the biofilm, respectively. 
DEHi partially inhibited the metabolic activity at all concentrations tested (3.125–200 mg/ml), 
acting throughout the development kinetics and especially in the early and intermediate phases 
(8h and 24h). However, SMIC80 of DEHi was not observed at any concentrations tested (3.125–
200 mg/ml). Therefore, FEHi showed higher C. albicans anti-biofilm potential under the test 
conditions. These data may contribute to the development of phytochemicals as adjuvants for 
oral prophylaxis and antisepsis or C. albicans anti-biofilm prosthetics, either as mouthwash or 
dentifrice. 
In a prior study (Bassi & Boriollo 2019), the anti-biofilm action of FLU, AB and NYS 
antifungals can be considered dose-, time- and surface-dependent and stronger when compared 
to FEHi and DEHi (i.e., higher anti-biofilm action at lower concentration), but above 
recommended concentrations for resistant planktonic cells (i.e., concentrations 7.8 higher for 
FLU, 500 higher for AB, and 3.9-125 to 15.6-500 higher for NYS) (CLSI 2008; Silva et al. 
2018; Bassi & Boriollo 2019). However, these relatively effective antifungal responses of C. 
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albicans anti-biofilm agents are obtained with overdose, probably due to the greater intrinsic 
resistance of biofilms when compared to planktonic cells. In such cases, the therapeutic 
approach should take into account dose-limiting toxicities associated with antifungal agents 
(i.e., infusion-related toxicities – chills, fever, hypotension or hypertension, hypoxia, nausea, 
vomiting and hypokalemia, sometimes resulting in ventricular fibrillation – and amphotericin 
B nephrotoxicity, nystatin hemolytic activity, and hepatotoxicity with triazole antifungal 
agents) and long-term risks, including recurrent drug interactions, organ dysfunction and skin 
reactions, and other malignancies (Lewis 2011; Boros-Majewska et al. 2015; Bellmann & 
Smuszkiewicz 2017). 
On the other hand, little preclinical evidence involving H. impetiginosus showed (i) 
absence of genotoxicity (clastogenicity and aneugenicity) dose- (0.5-2 g/kg), time- (24-48 h), 
and gender-independent (male and female) and relatively low systemic toxicity by 
micronucleus assay in mouse bone marrow (Boriollo et al. 2018), (ii) extensive DNA damage 
in liver cells from male rats (100, 300, and 500 mg/kg), except for blood cells (100 mg/kg) 
(Lemos et al. 2012), and (iii) factors indicating low toxicity profile (without LD50) due to absent 
death of mice even at high concentration (1, 3 and 5 g/Kg; p.o.) (Gonçalves de Miranda et al. 
2001). Thus, H. impetiginosus-related toxicological studies, including pharmacokinetics and 
pharmacodynamics studies, are required in order to identify potential human health risks and 
develop chemopreventive strategies. 
In addition, pre-incubation of specimens with FBS significantly enhanced the metabolic 
activity throughout the development kinetics of C. albicans biofilms, whether or not exposed 
to FEHi and DEHi. These findings agree with prior data found in the literature about the effect 
of AB, FLU and NYS antifungals on the development kinetics of in vitro C. albicans biofilm 
on varnished surfaces of vinyl polysiloxane (Silagum-Comfort Verniz®) (Bassi & Boriollo 
2019) and polystyrene surfaces (Ramage et al. 2004; Kipanga & Luyten 2017) preconditioned 
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in saliva or serum. For C. albicans, increased planktonic cell adhesion on surfaces 
preconditioned with serum has been attributed to serum proteins (e.g. albumin) which can 
increase binding sites and adhesion efficiency (Ramage et al. 2001). 
Confocal laser scanning microscopy (CLSM) has been considered an effective 
analytical tool and complementary to morphofunctional studies of biofilms (Chandra et al. 
2008; Silva et al. 2012; Gonçalves et al. 2015; Bassi & Boriollo 2019). The effects of FEHi and 
DEHi on biological parameters (percentage of non-viable cells based on cell membrane 
integrity) and magnitude (relative biomass and thickness) were considered identical under the 
conditions established in the CLSM assay (i.e., preconditioning in FBS and single concentration 
of FEHi and DEHi considered minimally desirable and unable to fully inhibit the cellular 
metabolic activity – 12.5 mg/ml). Prior studies showed treatments with antifungal agents (FLU, 
AB and NYS) at the same concentrations also had effects on both biological parameters 
(percentage of non-viable cells) and magnitude (relative biomass and thickness) of C. albicans 
biofilm development kinetics on specimens (Bassi & Boriollo 2019). The different 
development phases of C. albicans biofilm (1½h, 8h, 24h and 48h) did not significantly 
influence the percentage of non-viable cells and relative biomass with exposure to FEHi or 
DEHi. However, significant differences were observed between the initial developmental 
phases (1½h and 8h) and the maturation phase (48h) of C. albicans biofilm for the thickness 
parameter. Therefore, thickness is time-dependent, that is, C. albicans biofilms have elevated 
height in advanced stages of formation, with or without exposure to FEHi and DEHi. These 
findings agree with prior data about C. albicans biofilm development kinetics and exposure to 
antifungal agents (FLU, AB and NYS), except for the parameter of relative biomass, which was 
time-dependent (i.e., greater in volume in the advanced stages of biofilm formation), whether 
or not exposed to antifungals (Bassi & Boriollo 2019). This difference could be partially 
explained by the higher efficiency of antifungal action and lower concentration in C. albicans 
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biofilm development kinetics, when compared to the anti-biofilm action of FEHi and DEHi 
(i.e., mean absorbance of metabolic activities of FLU, AB, and NYS versus FEHi and DEHi; 
mean absorbance of FLU, AB and NYS closer to sterility controls versus absorbance data of 
FEHi and DEHi less close to sterility controls). Also, concentrations slightly above those used 
in the CLSM conditions could be tested to establish new parameters for plant extract assays. 
The CLSM assay results add information to studies about C. albicans biofilm on different 
preconditioned surfaces [e.g. poly(methyl methacrylate) (PMMA), silicone-based materials and 
dental resins] and anti-biofilm agents, so, the potential anti-biofilm action of FEHi and DEHi 
is described for the first time in the literature (Jyotsna Chandra et al. 2001; Ramage et al. 2002; 
Pierce et al. 2008; Silva et al. 2012; Bueno et al. 2015; Kipanga & Luyten 2017; Bassi & 
Boriollo 2019). 
Variable ultrastructural morphological characteristics of C. albicans were revealed by 
scanning electron microscopy (SEM) assay: dimorphism (yeast and hypha), microbial volume 
and microbial population density. FEHi and DEHi produced distinct effects throughout the 
adhesion and initial phases of C. albicans biofilm development kinetics, but identical effects of 
FEHi and DEHi were observed in the subsequent phases (intermediate and maturation). In the 
adhesion phase, FEHi induced (i) reduction in cell volume (yeast), (ii) decrease in the number 
of hypha, and (iii) decrease in cell adhesion density, while DEHi induced (i) reduced volume 
of dimorphic structures (yeast and hypha), (ii) increased proportion of coenocytic hypha, and 
(iii) small increase in cell density, in addition to reduced cellular metabolic activities and 
thickness. In the initial phase, FEHi induced (i) reduced volume of dimorphic structures (yeast 
and hypha), (ii) increased proportion of coenocytic hypha, and (iii) increased cell density, while 
DEHi induced (i) reduced volume of dimorphic structures (yeast and hypha), (ii) increase in 
yeast proportion, and (iii) maintenance of cell density, as well as reduced cellular metabolic 
activities and smaller thickness. The subsequent development stages of C. albicans biofilm 
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presented (i) reduced volume of dimorphic structures (yeast and hypha) (FEHi and 24-48h; 
DEHi and 24-48h), (ii) increase in the proportion of yeast (FEHi and 24-48h; DEHi and 48h), 
or maintenance of the proportion of yeast and coenocytic hypha (DEHi and 24h), and (iii) 
maintenance of cell density (FEHi and 24h; DEHi and 24h) or reduced cell density (FEHi and 
48h; DEHi and 48h) versus control, and reduced cellular metabolic activities and thickness in 
the intermediate (24h) or maturation (48h) phases. These results suggest that qualitative and 
quantitative phytochemical compositions of both extracts of H. impetiginosus are potentially 
distinct, influencing their effects on the ultrastructural morphological characteristics of C. 
albicans biofilm development kinetics, especially in the early phases. Extraction and drying 
methods to obtain plant extracts may influence the phytochemical composition of the final 
product and, consequently, produce variable pharmacological effects (Oliveira et al. 2016), 
according to the variation observed in this study due to the C. albicans anti-biofilm action of 
the hydroalcoholic (FEHi) and dry (DEHi) extracts of H. impetiginosus bark. 
Some phytochemicals (anthraquinones, naphthoquinones) of H. impetiginosus have 
been associated with potential antibacterial and antifungal activity (Portillo et al. 2001; Cwikla 
et al. 2009; Yamashita et al. 2009; Höfling et al. 2010; Jiménez-González et al. 2013). The 
pharmacological activities of this species have been related to saponins, flavonoids, coumarins 
and natural antibiotics, while the chemical profile reported in most studies showed quinones as 
the main active substances (Pereira et al. 2006). Secondary metabolites containing 1,4 and 1,2-
naphthoquinone moieties in their structure have been isolated from plants and presented 
interesting biological activities. Lapachol and β-lapachone, found in species of Handroanthus, 
have relevant effects against Candida albicans, Candida tropicalis and Cryptococcus 
neoformans, and are more active than ketoconazole, the reference standard (Park et al. 2006). 
However, the literature does not have results related to the anti-biofilm capacity of H. 
impetiginosus and/or its isolated compounds, so it is unprecedented information. The formation 
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of biofilms involves several stages, responses and cell interactions, and any intervention that 
may occur in biofilm kinetics may influence such development (Sangetha et al. 2009). This 
study shows relevant information about H. impetiginosus effect on C. albicans biofilm 
development kinetics on specimens and acquired films. 
 
Conclusion 
FEHi effectiveness is dose-dependent (on average, inhibition of metabolic activity starts 
at 100 mg/ml), surface-dependent (FBS positively influences biofilm resistance) and time-
dependent (8 or 1½ hour biofilms are more sensitive) regarding C. albicans biofilm 
development kinetics. SMIC80 of FEHi increases throughout biofilm development (SMIC80 of 
3.125, 6.25 and 200 mg/ml for the adhesion or initial, intermediate and maturation phases of 
biofilm stages, respectively). DEHi effectiveness is partially dose-dependent (on average at all 
concentrations tested), surface-dependent (FBS positively influences biofilm resistance) and 
time-dependent (8 or 24-hour biofilms are more sensitive) regarding C. albicans biofilm 
development kinetics. SMIC80 of DEHi is nonexistent at any concentrations tested (3.125–
200 mg/ml). FEHi has greater antimicrobial potential and, therefore, these data add preclinical 
information strategically employed in the development of new drugs, especially for oral or 
prosthetic prophylaxis and antisepsis for C. albicans anti-biofilm, either as mouthwash or 
dentifrice. 
Preconditioning with FBS ensures greater cellular metabolic activity in C. albicans 
biofilm developmental kinetics, whether or not exposed to FEHi and DEHi. 
FEHi or DEHi (at identical concentrations) have equal effects on the biological 
parameters (percentage of non-viable cells) and magnitude (relative biomass and thickness) 
throughout C. albicans biofilm development kinetics on the surface of the specimens 
preconditioned with FBS. This result confirms the hypothesis that viable (or unviable) cells, 
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labeled with LIVE/DEAD™, do not necessarily present metabolic activity (or metabolic 
inactivity) monitored by XTT reduction, as FEHi and DEHi have a dose-dependent effect on 
the metabolic activity of biofilms. Thickness variations are dependent on the development 
phases of C. albicans biofilm (time-dependent, i.e., greater thickness in the maturation phase), 
whether or not exposed to FEHi and DEHi. Percentages of non-viable cells and relative biomass 
of biofilm are invariable and, therefore, independent of C. albicans biofilm development phases 
(time-independent), whether or not exposed to FEHi and DEHi, possibly due to a relatively 
weak anti-biofilm action of extracts under test conditions (CLSM assay). 
FEHi and DEHi have distinct effects on the ultrastructural morphological characteristics 
(i.e., dimorphism, microbial volume and microbial population density), especially throughout 
the adhesion and initial development stages of C. albicans biofilm, but their actions are similar 
in the intermediate and maturation phases. 
Screening of the phytochemical composition of these extracts is being conducted by our 
research group in genotoxicity and cytotoxicity studies (in vivo and in vitro). The 
phytochemical composition of H. impetiginosus will potentially correlate with its C. albicans 
anti-biofilm effects (metabolic bioactivity, biological and magnitude parameters, ultrastructural 
morphological characteristics, and biofilm development stages). 
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3 CONCLUSÃO 
 
 Infere-se que a prescrição de nistatina para pacientes em uso de próteses dentárias com 
estomatite causada por espécies de Candida resistentes ou suscetíveis a outros 
antifúngicos, principalmente C. albicans, corrobora potencialmente o sucesso da terapia 
antifúngica clinicamente superficial. 
 O FEHi tem maior potencial de ação antimicrobiana e, portanto, estes dados agregam 
informações pré-clínicas empregadas estrategicamente ao desenvolvimento de novos 
fármacos, de modo especial para a profilaxia e antissepsia bucal ou protética anti-
biofilme de C. albicans, seja como colutórios ou dentifrícios. 
 O pré-condicionamento com BFS contribui significativamente para a cinética de 
desenvolvimento dos biofilmes de C. albicans sobre os corpos de prova, como resultado 
das maiores atividades metabólicas mesmo sob a influência da exposição dos 
antifúngicos FL e AB, exceto pela influência da NYS (i.e., sua ação efetiva independe 
das películas adsorvidas geradas a partir de BFS, AS ou AS+BFS). 
 O pré-condicionamento com BFS proporciona maior atividade metabólica celular na 
cinética de desenvolvimento dos biofilmes de C. albicans, mesmo sob a exposição aos 
FEHi e DEHi. 
 A exposição dos antifúngicos FL, AB e NYS em concentrações idênticas exerce efeito 
igualmente sobre os parâmetros biológico (percentual de non-viable cells) e de grandeza 
(relative biomass and thickness), durante a cinética de desenvolvimento dos biofilmes 
de C. albicans sobre os corpos de prova. Este fenômeno implica que células viáveis (i.e., 
marcadas com LIVE/DEAD™) não necessariamente apresentam atividades 
metabólicas (i.e., pelo ensaio do XTT), visto que a bioatividade da cinética do 
desenvolvimento dos biofilmes também é influenciada pelo tipo e concentrações de 
antifúngicos.  
93 
 
 
 Variações dos parâmetros de grandeza (relative biomass e thickness) é dependente das 
fases de desenvolvimento dos biofilmes de C. albicans sobre os corpos de prova, ao 
passo que os parâmetros biológicos (percentual de non-viable cells) tendem a ser 
constantes ao longo da cinética de formação dos biofilmes de C. albicans. Portanto, a 
manutenção de células viáveis de C. albicans, sob condições adversas, reveste-se de 
estruturas arquitetônicas dinâmicas e diferenciadas ao longo da cinética de formação 
dos biofilmes. 
 FEHi ou DEHi (em concentrações idênticas) atuam igualmente sobre os parâmetros 
biológico (percentual de non-viable cells) e de grandeza (relative biomass and 
thickness) ao longo a cinética de desenvolvimento dos biofilmes de C. albicans na 
superfície dos corpos de prova pré-condicionados em BFS. Este resultado confirma a 
hipótese de que células viáveis (ou inviáveis), marcadas com LIVE/DEAD™, não 
necessariamente apresentam atividades metabólicas (ou inatividades metabólicas), 
monitoradas pela redução do XTT, uma vez que FEHi e DEHi agem de modo dose-
dependentes sobre as atividades metabólicas dos biofilmes.  
 Variações da thickness são dependentes das fases de desenvolvimento do biofilme de 
C. albicans (tempo-dependente, i.e., maior thickness na fase de maturação), 
independentemente da exposição ou não aos FEHi e DEHi. Percentuais de non-viable 
cells e relative biomass of biofilm são invariáveis e, portanto, independentes das fases 
de desenvolvimento do biofilme de C. albicans (tempo-independentes), 
independentemente da exposição ou não aos FEHi e DEHi, possivelmente devido ao 
potencial de ação anti-biofilme relativamente fraco dos extratos sob as condições testes 
(CLSM assay). 
 FEHi e DEHi têm ações distintas sobre as características morfológicas ultra estruturais 
(i.e., dimorfismo, volume microbiano e densidade populacional microbiana), 
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especialmente ao longo das fases de adesão e inicial de desenvolvimento do biofilme de 
C. albicans, porém suas ações ocorrem semelhantemente nas fases intermediária e de 
maturação. 
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